5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones and methods of use therefor

ABSTRACT

The present invention relates to synthetic methods for the production of both optically active and racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones; 5-[(4-aryl)-3-butynyl]-3,4-dihydroxy-2(5H)-furanones; 5-(2-arylthio)ethyl-3,4-dihydroxy-2(5H)-furanones; and 5-(2-aryloxy)ethyl-3,4-dihydroxy-2(5H)-furanones. This invention further relates to the use of the above mentioned compounds as anti-inflammatory agents through their action as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1 and cyclooxygenase-2. The invention further relates to the use of such compounds in the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders such as Alzheimer&#39;s and Parkinson&#39;s disease wherein reactive oxygen species and inflammatory mediators are contributing deleterious factors.

This application is a Division of application Ser. No. 08/915,099, filed Aug. 20, 1997 now U.S. Pat. No. 6,005,000.

This Application claims priority from Provisional Applications Serial Nos. 60/024,440 and 60/024,586 both filed on Aug. 22, 1996.

FIELD OF THE INVENTION

The present invention relates generally to 5-substituted and 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones, methods of preparation therefor, and methods for their use.

BACKGROUND OF THE INVENTION

The aci-reductone 4-(4-chlorophenyl)-2-hydroxytetronic acid compound (CHTA) possesses antilipidemic and antiaggregatory properties which differ from those of the classical phenoxyactetic acids as has been disclosed in Witiak et al. J. Med. Chem., 1988, 31:1434-1445 and Kamanna et al., Lipids, 1989, 24:25-32. Although unsubstituted-, 2-alkyl- and 2-acyltetronic acids are frequently found in nature, the 2-hydroxy substituted tetronic acid redox system is found only in vitamin C and its closely related relatives (isoascorbic acid, erythroascorbic acid) and derivatives, and the macrolide antibiotic, chlorothricin.

The antiaggregatory activities of 2-hydroxytetronic acid aci-reductone compound (CHTA) are of interest since blood platelets are involved in the genesis of atherosclerosis. 2-Hydroxytetronic acid aci-reductones inhibit collagen-induced human platelet aggregation and secretion of [¹⁴ C]-serotonin in a concentration-dependent manner at equivalent doses, as reported in Witiak et al., J. Med. Chem., 1982, 25:90-93. The CHTA compound inhibits platelet function by a similar mechanism, involving arachidonic acid release. Redox analogues, such as 2-hydroxytetronic acid, function as antioxidants in membranes or interfere with free radical processes involved in the biosynthetic elaboration of cyclic prostaglandin endoperoxides (PGG₂ and PGH₂), and, subsequently, thromboxane A₂ from arachidonic acid.

The development of dual antioxidant-arachidonic acid (AA) metabolism inhibitors may provide added benefits over existing drugs for the treatment of diseases associated with oxidative stress and inflammation. Numerous conditions including asthma, rheumatoid arthritis, irritable bowel disease (IBD), adult respiratory distress syndrome (ARDS), atherosclerosis, ischemia/reperfusion injury, restenosis, neurodegenerative disorders and initiation and promotion of carcinogenesis correlate with abnormally high levels of reactive oxygen species (ROS). Antioxidant-based therapies including both natural antioxidants (e.g., vitamin E, vitamin C and SOD), and synthetic antioxidants (e.g., 4-aryl-2-hydroxytetronic acids¹, 2-O-alkyl ascorbic acids, probucol and tirilazad mesylate) have been, or are currently being, investigated for the treatment of a number of these conditions.

Previously, the S-arachidonic acid aci-reductone analog (S)-3,4-dihydroxy-5 [(all Z)-3,6,9,12-octadecatraenyl]-2 (5H)-furanone, was identified as a stereoselective and potent arachidonic acid metabolic inhibitor. This compound inhibits both PGE₂ and LTB₄ production in stimulated macrophages (IC₅₀ =20 μM) and blocks AA-induced platelet aggregation (AAIPA) with an IC₅₀ <10 μM. Dual cyclooxygenase (COX) and lipoxygenase (LO) activity coufd be important in preventing substrate shunting in the arachidonic acid cascade. Although this compound demonstrates an encouraging biological profile, both its instability and labored synthesis render this compound less than satisfactory as a therapeutic agent.

Thus, there exists a need for new therapeutic agents which exhibit activity as antioxidants and arachidonic acid metabolism inhibitors. It is to this aim that the present invention is directed.

SUMMARY OF THE INVENTION

The present invention relates to 5-substituted and 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones of the general formula I ##STR1## wherein R is hydrogen, phenyl or lower alkyl; L is a linker moiety selected from the group consisting of oxygen, sulfur, nitrogen, acetylene, a cis or trans carbon-carbon double bond, an ester, carbonate, urea, amide and carbamate; m is 0 or 1; n is 0 to 4; Aryl is a substituted or unsubstituted aryl group; with the proviso that when R is hydrogen, then either m or n is not zero, and the pharmaceutically acceptable salts thereof.

In various preferred embodiments of the present invention, these compounds are represented by four structural subclasses of compounds. Thus, in one preferred embodiment, the compounds are 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones of the structural formula Ia ##STR2## wherein R and Aryl are as hereinbefore defined. Most preferably, in the compounds of formula (Ia), R is a methyl, 1-propyl or 2-methylpropyl group; and Aryl is a phenyl, or substituted phenyl, such as 1,1¹ -biphenyl, 4-chlorophenyl or 2-methylpropylphenyl group.

In a second preferred embodiment, the compounds are 5-(aryl alkynyl)-3,4-dihydroxy-2(5H)-furanones of the structural formula Ib ##STR3## wherein n and Aryl are as hereinbefore defined. Most preferably, in the compounds of formula Ib, n is 2 and Aryl is naphthyl or a substituted phenyl such as 2-methylphenyl, 2-hexenyl phenyl, 2-phenylthiomethylphenyl or pentylthiomethyl phenyl.

In a third preferred embodiment, the compounds are 5-(arylthio)alkyl-3,4-dihydroxy-2(5H)-furanones of the structural formula Ic ##STR4## wherein n and Aryl are as hereinbefore defined. Most preferably, in the compounds of Formula Ic, n is 2 and the Aryl substituent is napthyl or 4,5-diphenyloxazole.

In a fourth preferred embodiment, the compounds are 5-(aryloxy)alkyl-3,4-dihydroxy-2(5H)-furanones of the structural formula Id ##STR5## wherein n and Aryl are as hereinbefore defined. Most preferably, in the compounds of formula Id, n is 2 and Aryl is a substituted phenyl or heteroaryl compound such as 1,1² biphenyl-4 yl, 4-phenoxyphenyl, flavonyl, dibenzofuranyl, quinolinyl and naphthyl.

The racemic 5,5-disubstituted analogs of formula Ia are prepared by reacting an ethyl benzoylformate with a Grignard reagent and trapping the intermediate alkoxide anion with benzyloxyacetyl chloride, and subsequently adding lithium diisopropylarnide to generate the corresponding 3-benzyloxy-5,5-disubstituted-4-hydroxy-2(5H)-furanones. Cleavage of the benzyl group by hydrogenolysis provides racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones of formula Ia.

The enantiomerically pure 5,5-disubstituted analogs of formula Ia are synthesized by reacting ethyl benzoylformate with a Grignard reagent, followed by ester saponification and resolution of the resultant 2-aryl-2-substituted-2-hydroxy acid by crystallizing with a suitable optically pure chiral amine to provide the optically pure compounds with non-racemisable stereocenters. Acid esterification, acylation of the hydroxyl group with benzyloxyacetyl chloride, LDA-induced intramolecular Claisen cyclization and reductive cleavage of the benzyl protecting group generates the 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones of formula Ia having high enantiomeric purity.

The 5-(aryl alkynyl)-3,4-dihydroxy-2(5H)-furanones of formula Ib are synthesized in a convergent manner by coupling 5-(alkynyl)-3,4-dihydroxy-2(5H)-furanone with aryliodides by employing a catalytic amount of Pd(PPh₃)₄. The starting material, 5-(alkynyl)-3,4-dihydroxy-2(5H)-furanone, is synthesized in four steps. For instance, intermolecular Claisen reaction between α-trimethylsilyloxy-γ-butyrolactone and ethyl benzyloxyacetate yields 3-benzyloxy-4-hydroxy-5-(2-hydroxyethyl)-2(5H)-furanone. Iodination (I₂, PPh₃, imidazole), subsequent iodo displacement with lithium acetylide, and benzyl group cleavage yields, for instance, the 5-(3-butynyl)-3,4-dihydroxy-2(5H)-furanone coupling precursor.

The 5-(arylthio)alkyl-3,4-dihydroxy-2(5H)-furanones of formula Ic are produced by reacting a 3,4-dihydroxy-5-(iodoalkyl)-2(5H)-furanone with the lithium salt of a substituted arylthiol. The starting material, 3,4-dihydroxy-5-(2-iodoalkyl)-2(5H)-furanone is produced by benzyl group cleavage of 3-benzyloxy-4-hydroxy-5-(2-iodoalkyl)-2(5H)-furanone.

The 5-(aryloxy)alkyl-3,4-dihydroxy-2(5H)-furanones of formula Id are prepared by coupling 3,4-dibenzyloxy-5-(hydroxyalkyl)-2(5H)-furanone with an appropriately substituted phenol according to the Mitsunoble reaction. Subsequent benzyl group cleavage by hydrogenation yields the desired 5-(aryloxy) alkyl-3,4-dihydroxy-2(5H)-furanone.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "alkenyl" means an organic, alkanyl group containing one or more double bonds and which can optionally be substituted by one or more halogen, lower alkanyl, alkoxy, aromatic or heteroaromatic groups. Examples of unsubstituted alkenyl groups include those such as 3-butenyl, 3- or 4-pentenyl, and the like. In a similar fashion, the term "alkynyl" refers to an organic, alkanyl group containing one or more triple bonds, of which 3-butynyl, 3- or 4-pentynyl and the like are representative.

The term "substituted or unsubstituted aryl", as utilized herein, means an organic, aromatic group which can be unsubstituted or substituted by one or more lower alkyl, lower alkenyl, lower alkenynyl, loweralkylthio, loweralkylsulfonyl, loweralkylsulfonylamino, aromatic or heteroaromatic groups. Examples of unsubstituted aryl groups include phenyl, pyridyl, thiophenyl, furyl, pyrrolyl and the like. Examples of substituted aryl groups include those such as alkyl-substituted aryl, e.g., tolyl, 3-methylpyridyl, 2,3-dimethylphenyl, 4-ethylphenyl, 4-isobutylphenyl; alkoxysubstituted aryl, e.g., 4-methoxyphenyl; loweralkylthio or loweralkylsulfonyl-substituted aryl, e.g., 1-propylthiophenyl, 1-pentylsulfonylphenyl, lower alkenyl substituted phenyl, e.g., 4-(2-(2Z-hexenyl]phenyl and aryl-substituted aryl, e.g., 1,1'-biphenyl and naphthyl. Complex aryl groups such as those derived from flavone, dibenzofuran, 1,8-naphthalimide, 1,8-naptholsultam, quinoline, 4,5-diphenyl-2-thio-1,3-oxazole, and naphthalenethiol can also be utilized as substituent groups. Particularly preferred are compounds wherein a 2- or 2,3-disubstitution pattern (relative to the alkenenyl or alkynenyl group) is present.

As used herein, the term lower "alkyl" means straight- or branched-chain saturated aliphatic hydrocarbon groups preferably containing 1-6 carbon atoms. Representative of such groups are methyl, ethyl, isopropyl, isobutyl, butyl, pentyl, hexyl and the like,

The term "alkoxy" means a lower alkyl group attached to the remainder of the molecule by oxygen. Examples of alkoxy include methoxy, ethoxy, propoxy, isopropoxy and the like.

The compounds of formula I can be formed as mixtures of enantiomers, as well as cis/trans isomers, due to the asymmetric carbon atoms of the ring structure and the double bonds present in the substituents. The present invention contemplates the use of both the individual isomers, as well as the racemic or cis/trans mixtures or both.

The present invention relates to 5-substituted-and 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones of the general formula, ##STR6## wherein R is hydrogen, phenyl, or a lower alkyl; L is a linker moiety selected from the group consisting of oxygen, sulfur, nitrogen, acetylene, a cis or trans carbon--carbon double bond, an ester, carbonate, urea, amide and carbamate; m is 0 or 1, n is 0 to 4, Aryl is a substituted or unsubstituted aryl group; with the proviso that when R is hydrogen, then either m or n is not zero; and the pharmaceutically acceptable salts thereof.

In general, the compounds of formula I wherein m and n are zero are prepared by:

a) reacting a benzoylformate of the formula, ##STR7## wherein Alk is a lower alkyl group, Aryl is as hereinbefore defined with an organometalic reagent RMX wherein M is a group I or group II metal, X is a halogen, and R is as hereinbefore defined, to form an intermediate alkoxide of the formula, ##STR8## wherein Aryl, R, M, Alk and X are as hereinbefore defined. The intermediate alkoxide is treated with a benzyloxyaicetyl chloride, wherein Bn is a protecting group such as benzyl or a substituted derivative thereof, to provide an intermediate diester of the formula, ##STR9## wherein Aryl, R and Alk are as hereinbefore defined; (b) Intramolecular Claisen cyclization of the diester of formula IV to the tetronic cid of the formula, ##STR10## wherein Aryl, R and Bn are as hereinbefore defined; and (c) cleaving the benzyl protecting group of formula V by catalytic hydrogenation to yield the desired 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanone of the general formula I wherein Aryl and R are as hereinbefore defined, and m and n are 0.

Step (a) of the instant process utilizes as starting material, the appropriate benzoyl formate of the formula II wherein Aryl and Alk are as hereinbefore defined which can be purchased through commercial suppliers, or, if not commercially available, synthesized according to literature procedures. Benzoylformates are prepared by mixing an aryl compound, alkyl oxalylchloride and AlCl₃ (or suitable Lewis acid) in a 1.0/1.1/1.1 mixture in 1,2-dichloroethane (or suitable solvent) at 0₋₋ to 10₋₋ C. with vigorous stirring and subsequently stirring the reaction mixture at 25₋₋ C. for 24 hours according to the method of Kuchar et al., Coll. Czech. Chem. Commun., 49: 122-136 (1984).

A process for the synthesis of enantiomerically pure analogs of the formula I wherein m and n are both zero comprises:

(a) reacting an optically pure 2-hydroxyester of the formula ##STR11## wherein Aryl, R and Alk are as hereinbefore defined with a benzyloxyacetyl chloride, wherein Bn is as hereinbefore defined, to provide an intermediate diester of the formula, ##STR12## wherein Aryl, R, Bn, Alk and R are as hereinbefore defined; (b) Intramolecular Claisen cyclization of the diester of formula VII to the tetronic acid of the formula, ##STR13## wherein Aryl, R and Bn are as hereinbefore defined; and (c) cleaving the benzyl protecting group of formula VIII by catalytic hydrogenation to yield the desired optically pure 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanone of the general formula I wherein Aryl and R are as hereinbefore defined, and m and n are both zero.

Step (a) of this process utilizes as starting material, an optically pure 2-hydroxyester of the formula VI, wherein Aryl, R and Alk are as hereinbefore defined, which can be purchased through commercial suppliers or, if not commercially available, synthesized according to literature procedures. Reaction of a benzoylformate with an organometalic reagent RMX, wherein R, M, and X are as hereinbefore defined, produces racemic 2-hydroxyesters of the formula VI, wherein aryl, R and Alk are as hereinbefore defined. Ester saponification with, for example, 1.0M NaOH, resolution with an optically pure amine base using the method of Saigo et al., Bull. Chem. Soc. Jpn., 55: 1188-1190 (1982) and esterification of the acid with, for example an etheral solution of CH₂ N₂, provides optically pure 2-hydroxyesters of the formula VI.

A process for the synthesis of analogs of formula I wherein R is hydrogen, Aryl is as hereinbefore defined, m is 1 n=2, and L is an oxygen, ester, N-sulfonamide or N-irnide linkage comprises:

(a) reacting a 3-benzyloxy-4-hydroxy-5-(2-hydroxyethyl)-2(5H)-furanone of the formula, ##STR14## wherein Bn is as hereinbefore defined with one equivalent of BnBr and one equivalent of triethlyamine in THF for 5 hours at 65₋₋ C. to provide 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone of the formula, ##STR15## wherein Bn is as hereinbefore defined; (b) reacting the 3,4-dibenzyloxy-2(5H)-furanone of the formula X with an aryl alcohol (i.e. phenol), carboxylic acid, sulfonamide, or phthalimide, wherein aryl is as hereinbefore defined, under Mitsunoble conditions to provide 3,4-dibenzyloxy-2(5H)-furanones of the formula, ##STR16## wherein Aryl and Bn are as hereinbefore defined, L is an oxygen, ester, N-sulfonamide or N-imide linkage and n=2; and

(c) cleaving the benzyl protecting groups of formula XI by catalytic hydrogenation to yield the desired 5-substituted-3,4-dihydroxy-2(5H)-furanone of the general formula I wherein R is hydrogen, Aryl is as hereinbefore defined, m is 1, n=2, and L is an oxygen, ester, N-sulfonamide or N-imide linkage.

A process for the synthesis of analogs of the formula I wherein R is hydrogen, Aryl is as hereinbefore defined, m is 1, n=2, and L is a sulfur linkage comprises:

(a) Iododination of the 3-benzyloxy-4-hydroxy-5-(2-hydroxyethyl)-2(5H)-furanone of the formula IX with I₂, PPh₃ and imidazole in CH₃ CN/ether (1/5) to produce the 3-benzyloxy-4-hydroxy-5-(2-iodoethyl)-2-(5H)-furanone of formula, ##STR17## wherein Bn is as hereinbefore defined; (b) benzyl group cleavage by first treating the furanone of formula XII with acetyl anhydride and pyridine in CH₂ Cl₂ for 2 hours, followed by removal of all volatile substances in vacuo and subsequent treatment with boron trichloride to yield 3,4-dihydroxy-5-(2-iodoethyl)-2(5H)-furanone of the formula; ##STR18## (c) reaction of a compound with the formula XIII with three mole equivalents of the lithium salt of an arylthiol, wherein aryl is as hereinbefore defined, provides compounds of the formula I wherein Aryl is as hereinbefore defined, n=2, R=H, and L is sulfur.

A process for the synthesis of analogs of the formula I wherein R is hydrogen, Aryl is as hereinbefore defined, m is 1, n=2, and L is an acetylene or carbon--carbon double bond linkage comprises:

(a) reaction of 5-(2-iodoethyl)-2-(5H)-furanone of the formula XII with lithium acetylide ethylenediamine complex in HMPA at -5₋₋ C. to make 3-benzyloxy4-hydroxy-5-(3-butynyl)-2-(5H)-furanone of formula, ##STR19## wherein Bn is as hereinbefore defined; (b) benzyl group cleavage by first treating the furanone of formula XIV with acetyl anhydride and pyridine in CH₂ Cl₂ for 2 hours, followed by removal of all volatile substances in vacuo and subsequent treatment of the remaining residue with boron trichloride to yield compounds of the general formula; ##STR20## (c) coupling the 5-(3-butynyl)-2(5H)-furanone of formula XV with an aryliodide to provide analogs of the formula I, wherein Aryl is as hereinbefore defined, n=2, R=H and L is an acetylene linker;

(d) reduction of the acetylene moiety by the addition of 1 mole equivalent of H₂ by catalytic hydrogenation under Lindlar conditions to yield compounds of formula I wherein Aryl is as hereinbefore defined, n=2, R=H and L is a carbon--carbon cis double bond; and

(e) reduction of the acetylene moiety by the addition of 2 mole equivalent of H₂ by catalytic hydrogenation to yield compounds of formula I wherein Aryl is as hereinbefore defined. m=0, n=4, and R is hydrogen.

In a composition aspect, the present invention encompasses novel pharmaceutical compositions comprising the compounds of the general formula I, together with a physiologically acceptable carrier or excipient, in an amount sufficient to have antilipidemic, antiaggregatory or antiinflammatory activities in an animal or patient. The compounds and their compositions of the present invention are thus useful in the treatment or prevention of atherosclerotic disorders, as well as in the treatment of various pathologies in which acute and chronic inflammation occur.

The starting materials utilized in the synthesis of the compounds of formula I are known in the art and/or are preparable by methods described herein. Where the pure optical isomers of these compounds are desired, numerous methods exist for the manufacture of optically active and optically pure derivatives of the necessary starting materials. Also, a wide range of chiral bases can be used to starting materials and intermediate products. Partial separation of enantiomers can typically accomplished with optically active solvents such as (-)-menthone, (-)-menthyl acetate and (+)-limonene. Anion-exchange chromatography using a chiral stationary phase constructed of 1-p-nitrophenyl-2-amino-1,3-propanediol, or chromatography through starch successfully separates mandelic acid enantiomers.

The invention also provides for pharmaceutical compositions comprising the compounds of formula I above, as well as their physiologically acceptable salts (such as, for example, Na⁻, K⁺, NH₄ ⁺).

The compounds of the invention have antilipidemic and antiaggregatory activity and are thus useful in the treatment or prevention of atherosclerotic disorders. Additionally, the compounds of the invention possess the ability to inhibit the activity of cyclooxygenase and 5-lipooxygenase in standardized assays for such activity, thus making them useful for the treatment of pathologies involving acute or chronic inflammation, such as inflammatory bowel disease, asthma, adult respiratory distress syndrome (ARDS) and various forms of arthritis.

Biological Evaluation

The compounds of the invention were screened for their anti-inflammatory activity using a series of in vitro tests the details of which are given below. The activity of various compounds against 5-lipoxygenase, cycloxygenase-1, cycloxygenase-2 and lipid peroxidase was evaluated. Results of the screening procedures are included in TABLE 1, and the activity against 5-lipoxygenase at a test concentration of 1 μM in Table II.

5-Lipoxygenase Screen

5-Lipoxygenase catalyzes the oxidative metabolism of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HETE), the initial reaction leading to the formation of the leukotrienes. Briefly, the testing procedure utilizes a crude enzyme preparation from rat basophilic leukemia cells (RBL-1) according to the methods of T. Shimuzu et al. Pro. Natl. Acad. Sci. 81:689-693 (1984) and R. W. Egan et al, J. Biol. Chem. 260: 11554-11559 (1985). Test compounds are pre-incubated with the enzyme preparation for 5 minutes at room temperature and the reaction is initiated by the addition of arachidonic acid. Following an 8 minute incubation at room temperature, the reaction is terminated by the addition of citric acid and concentrations of 5-HETE are determined by RIA. Compounds are screened at 30 μM. Under these conditions the reference compound phenidone has an IC₅₀ of 30 μM.

Cyclooxygenase-1 Screen

Cyclooxygenase-1 is involved in the formation of prostaglandins and thromboxane via the oxidative metabolism of arachidonic acid. Briefly, cyclooxygenase from ram seminal vesicles is incubated with arachidonic acid (100 μm) for 2 minutes at 37° C. in the presence or absence of test compounds according to the methods of A. T. Evans et al., Biochem. Pharm. 36:2035-2037 (1987) and R. Boopathy et al., Biochem J. 239:371-377 (1968). The assay is terminated by the addition of trichloroacetic acid and cyclooxygenase activity is determined by reading the absorbance at 530 nm. Compounds are screened at 300 μM. Under these condition the reference compound aspirin has an IC₅₀ value of 240 μM.

Cyclooxygenase-2 Screen

Cyclooxygenase-2, also known as prostaglandin H synthetase-2, catalyzes the rate-limiting step in the synthesis of inflammatory prostaglandins. In this reaction cyclooxygenase-2 catalyzes the oxygenation of unesterified precursors to form cyclic endoperoxide derivatives, including prostaglandin H. Briefly, cyclooxygenase-2 from sheep placenta, 14 μg/assay tube, is incubated with arachidonic acid (500 μM) for 1.5 minutes at 27° C. in the absence or presence of test compounds according to the methods of A. T. Evans, et al., Biochem Pharm. 36:2035-2037 (1987) and M. G. O'Sullivan et al., Biochem. Biophys. Res. Comm. 187: 1123-1127 (1992). The assay is terminated by the addition of trichloroacetic acid and cyclooxygenase activity is determined by reading the absorbance at 532 nm. Compounds are screened at 300 μM. Under these conditions the reference compound NS-398 exhibited 77% inhibition at 300 μM.

Lipid Peroxidation Screen

Lipid peroxidation is a consequence of various stimuli, including reactive free radicals. Polyunsaturated fatty acids associated with plasma membranes are degraded due to enzymatic induction by reactive agents such as CCl₄, leading to cellular damage. Briefly, microsomes are prepared from rat livers and the protein concentration is determined according to the method of D. Mansuy et al., Biochem. Biophys. Res. Comm. 135:1015-1021 (1986). A reaction mixture consisting of 2 mg of the microsomal preparation, an NADPH generating system, 20 mM CCl₄ and test compound are incubated for 12 minutes at 37° C. The reaction is terminated by the addition of a mixture of thiobarbituric acid and trichloroacetic acid. The absorbance is read at 535 nm and is proportional to the concentration of malondialdehyde. Compounds are screened at 300 μM. Under these conditions the reference compound, alpha-tocopherol has an IC₅₀ value of 280 μM.

                                      TABLE I                                      __________________________________________________________________________                                                (PERCENT INHIBITION)                Example                                    COX-1                                                                               COX-2                                                                               5-LO LPO                    #  Compound Name (300 μM) (300 μM) (30 μM) (300 μM)              __________________________________________________________________________     1     3,4-Dihydroxy-5-methyl-5-phenyl-2(5H)-furanone                                                                      -12  3    58   63                     2 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone 33 22                                                                 107 78                 3 3,4-Dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-furanone 2                                                                 -4 99 78                                                                        4 5-(4-Chloroph                                                               enyl)-3,4-dihydr                                                               oxy-5-methyl-2(5                                                               H)-furanone 2                                                                  24 2 54                                                                         5 5-[(1,1'-Biph                                                               enyl)-4-yl]-3,4-                                                               dihydroxy-5-prop                                                               yl-2(5H)-furanon                                                               e 13 22 99 70                                                                   6 5-[(1,1'-Biph                                                               enyl)-4-yl]-3,4-                                                               dihydroxy-5-(2-m                                                               ethylpropyl)-2(5                                                               H)-furanone 67                                                                 46 96 82                                                                        7 5-[(1,1'-Biph                                                               enyl)-4-yI]-3,4-                                                               dihydroxy-5-phen                                                               yl-2(5H)-furanon                                                               e 52 34 102 73                                                                  8 3,4-Dihydroxy                                                               -5,5-diphenyl-2(                                                               5H)-furanone 15                                                                17 94 70                                                                        9 3,4-Dihydroxy                                                               -5-(4-isobutylph                                                               enyl)-5-(1-propy                                                               l)-2(5H)-furanon                                                               e 25 19 82 79                                                                   10 3,4-Dihydrox                                                               y-5-(4-isobutylp                                                               henyl)-5-phenyl-                                                               2(5H)-furanone                                                                 43 34 106 89                                                                    11 (S)-(+)-5-[(                                                               1,1'-Biphenyl)-4                                                               -yl]-3,4-dihydro                                                               xy-5-methyl-2(5H                                                               )-furanone 34                                                                  10 101 71                                                                       12 (R)-(-)-5-[(                                                               1,1'-Biphenyl)-4                                                               -yl]-3,4-dihydro                                                               xy-5-methyl-2(5H                                                               )-furanone 10                                                                  12 101 62                                                                       13 (R)-(-)-3,4-                                                               Dihydroxy-5-meth                                                               yl-5-[4-(2-methy                                                               lpropyl)phenyl]-                                                               2(5H)-furanone                                                                 12 14 102 76                                                                    14 (S)-(+)-3,4-                                                               Dihydroxy-5-meth                                                               yl-5-[4-(2-methy                                                               lpropyl)phenyl]-                                                               2(5H)-furanone                                                                 12 18 96 66                                                                     15 3,4-Dihydrox                                                               y-5-[2-(4-phenox                                                               y)phenoxyethyl]-                                                               2(5H)-furanone                                                                 9 -4 100 -5                                                                     16 3,4-Dihydrox                                                               y-5-[2-(flavone-                                                               6-oxy)ethyl]-2(5                                                               H)-furanone 17                                                                 2 100 76                                                                        17 5-[2-(Dibenz                                                               ofuran-2-oxy)eth                                                               yl]-3,4-dihydrox                                                               y-2(5H)-furanone                                                                17 21 99 74                                                                    18 3,4-Dihydrox                                                               y-5-[2-(1-naphth                                                               oxy)ethyl]-2(5H)                                                               -furanone 11                                                                   -12 99 71                                                                       19 3,4-Dihydrox                                                               y-5-[2-(1,8-naph                                                               thalimide)-N-eth                                                               yl]-2(5H)-furano                                                               ne 9 2 86 68                                                                    20 3,4-Dihydrox                                                               y-5-[2-(1,8-naph                                                               thosultam)-N-eth                                                               yl]-2(5H)-furano                                                               ne -15 13 91 61        21 3,4-Dihydroxy-5-[2-(diphenylmethane-2-oxy)ethyl]-2(5H)-furanone 12                                                                  10 101 68                                                                       22 5-[2-((1,1'-                                                               Biphenyl)-4-oxy)                                                               ethyl]-3,4-dihyd                                                               roxy-2(5H)-furan                                                               one 18 10 99 74        23 3,4-Dihydroxy-5-[2-(quinoline-2-oxy)ethyl]-2(5H)-furanone 8 -2 93 69        24 3,4-Dihydroxy-5-[2-(4,5-diphenyl-1,3-oxazole-2-thio)ethyl]-2(5H)-fura                                                               none 76 68 113                                                                 78                     25 3,4-Dihydroxy-5-[2-(naphthyl-1-thio)ethyl]-2(5H)-furanone 6 19 102                                                                  74                     26 3,4-Dihydroxy-5-[2-(naphthyl-2-thio)ethyl]-2(5H)-furanone 12 12 101                                                                 77                     27 3,4-Dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone 5 20 42 59                                                                     28 3,4-Dihydrox                                                               y-5-[(4-(2-methy                                                               l)phenyl)-3-buty                                                               nyl]-2(5H)-furan                                                               one 4 15 58 61                                                                  29 3,4-Dihydrox                                                               y-5-[(4-(2-(2Z-h                                                               exenyl))phenyl)-                                                               3-butynyl]-2(5H)                                                               -furanone 55 26                                                                81 72                  30 3,4-Dihydroxy-5-[(4-(2-(phenylthio)methyl)phenyl)-3-butynyl]-2(5H)-fu                                                               ranone 26 16                                                                   100 62                 31 3,4-Dihydroxy-5-[(4-(2-phenylsulfonamide-(N-butyl)-3-butynyl]-2(5H)-f                                                               uranone 7 23 81                                                                73                     32 3,4-Dihydroxy-5-[4-(2-naphthyl)-3-butynyl]-2(5H)-furanone 34 23 98                                                                  75                     33 3,4-Dihydroxy-5-[(4-(2-(propylthio)methyl)phenyl)-3-butynyl]-2(5H)-fu                                                               ranone 37 20 84                                                                74                     34 3,4-Dihydroxy-5-[(4-(2-(1-pentylthio)methyl)phenyl)-3-butynyl]-2(5H)-                                                               furanone 67 43                                                                 92 63                  35 3,4-Dihydroxy-5-[(4-(2-(propylsulfonyl)methyl)phenyl)-3-butynyl]-2(5H                                                               )-furanone 25                                                                  13 30 60                                                                        36 3,4-Dihydrox                                                               y-5-[2-(4-(4-flu                                                               orophenylmethyl)                                                               thiophene)-(3-bu                                                               tynyl)]-2(5H)-                                                                 NT NT 85@1 NT                                                                    furanone                                                                      37 3,4-Dihydrox                                                               y-5-(4-phenylbut                                                               anyl)-2(5H)-fura                                                               none NT NT NT                                                                  NT                     38 3,4-Dihydroxy-5-[(4-phenyl)-3Z-butenyl]-2(5H)-furanone NT NT NT NT                                                                   39 3,4-Dihydrox                                                               y-5[(4-(2-methyl                                                               )phenyl)-3Z-bute                                                               nyl]-2(5H)-furan                                                               one NT NT NT NT        40 3,4-Dihydroxy-5[(4-(2-(2Z-hexenyl))phenyl)-3Z-butenyl]-2(5H)-furanone                                                                38 25 99            __________________________________________________________________________                                                               65              

                                      TABLE II                                     __________________________________________________________________________     The effect of various aci-reductones on 5-Lipoxygenase (5-LO)                    at a test concentration of 1 μM                                                                                 Percent Inhibition                         Example  of 5-LO at a test                                                     # Compound Name Conc. of (1 μM)                                           __________________________________________________________________________     2    5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone                                                  15                                         5 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-propyl-2(5H)-furanone 68                                                 6 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihy                                           droxy-5-(2-methylpropyl)-2(5H)-furan                                           one 70                                     7 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-phenyl-2(5H)-furanone 61                                                 8 3,4-Dihydroxy-5,5-diphenyl-2(5H)-                                           furanone 15                                9 3,4-Dihydroxy-5-(4-isobutylphenyl)-5-(1-propyl)-2(5H)-furanone 40                                                 10 3,4-Dihydroxy-5-(4-isobutylpheny                                           l)-5-phenyl-2(5H)-furanone 64                                                   11 (S)-(+)-5-[(1,1'-Biphenyl)-4-yl]                                           -3,4-dihydroxy-5-methyl-2(5H)-furano                                           ne 59                                      12 (R)-(-)-5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanon                                           e 60                                       13 (R)-(-)-3,4-Dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-fur                                           anone 59                                   14 (S)-(+)-3,4-Dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-fur                                           anone 50                                   15 3,4-Dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone 52                                                    16 3,4-Dihydroxy-5-[2-(flavone-6-ox                                           y)ethyl]-2(5H)-furanane 54                 17 5-[2-(Dibenzofuran-2-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone 60                                                  18 3,4-Dihydroxy-5-[2-(1-naphthoxy)                                           ethyl]-2(5H)-furanone 49                   20 3,4-Dihydroxy-5-[2-(1,8-naphthosultam)-N-ethyl]-2(5H)-furanone 38                                                21 3,4-Dihydroxy-5-[2-(diphenylmeth                                           ane-2-oxy)ethyl]-2(5H)-furanone 62                                              24 3,4-Dihydroxy-5-[2-(4,5-diphenyl                                           -1,3-oxazole-2-thio)ethyl]-2(5H)-fur                                           anone 71                                   25 3,4-Dihydroxy-5-[2-(naphthyl-1-thio)ethyl]-2(5H)-furanone 56                                                     26 3,4-Dihydroxy-5-[2-(naphthyl-2-t                                           hio)ethyl]-2(5H)-furanone 54                                                    29 3,4-Dihydroxy-5-[(4-(2-(2Z-hexen                                           yl))phenyl)-3-butynyl]-2(5H)-furanon                                           e 56                                       30 3,4-Dihydroxy-5-[(4-(2-phenylthio)methyl)phenyl)-3-butynyl]-2(5H)-fur                                           anone 70                                   32 3,4-Dihydroxy-5-[(4-(2-naphthyl)-3-butynyl]-2(5H)-furanone 66                                                    46 3,4-Dihydroxy-5-[2-(4-(4-fluorop                                           henylmethyl)thiophene)-(3-butynyl)]-                                           2(5H)- 91; IC.sub.50 = 160 nM                                                    furanone                               __________________________________________________________________________

Nuclear factor-κB exists in the cytoplasm of most cells bound to a natural inhibitor protein IκB. In a complex cascade, extracellular stimulation by cytokines such as TNF-α or interleukin-1 (IL1), viruses, lipopolysaccharide (LPS) or UV-radiation results in the production of second messenger reactive oxygen species (ROS). Increased ROS concentrations are important mediators, which instigate the process of IκB disassociation from the NF-κB complex enabling NF-κB to migrate into the cell nucleus. Recent findings demonstrate that low levels of H₂ O₂ activate NF-κB and that a number of antioxidants inhibit this activation process. The antioxidants pyrrolidone dithiocarbamate (PDTC) and N-acetyl-cysteine (NAC) inhibit both the H₂ O₂ and extracellular cytokine-induced activation of NF-κB in a concentration dependent manner. Steroids such as dexamethasone are potent anti-inflammatory agents in part, because they stimulate the gene synthesis of IκB, leading to inhibition of NF-κB. The mechanism by which these aci-reductones block NF-κB nuclear translocation is not clear, but is likely related to their antioxidant properties. However, the possibility that they specifically interact with a biomolecule involved in NF-κB activation has not been disregarded.

    ______________________________________                                                          Concentration                                                                            % Inhibition                                        ______________________________________                                         Test Compound                                                                    3,4-Dihydroxy-5-[4-(2-naphthyl)-3-  30 nM 90%                                  butynyl]-2(5H)-furanone                                                        Reference Compounds                                                            Dexamethasone 1000 nM 60%                                                      Pyrrolidone dithiocarbamate (PDTC) 10,000 nM   50%                             N-Acetyl-cysteine (NAC) 1000 nM  0%                                          ______________________________________                                    

Experiments measuring test agents effect on NF-κB nuclear membrane translocation were performed with NR8383 cells, which are transformed rat alveolar macrophages. Cells were treated simultaneously with LPS (1 μg/ml) and the test compounds (10 and 30 nM). In addition, some compounds were tested at doses of 10 and 30 μM. Untreated control cells and cells treated with LPS alone were tested in each experiment. Cells were harvested 6 hours after treatment. Nuclear proteins were extracted, frozen and quantified using the Bradford assay. Electrophoretic mobility shift assays (EMSA) were subsequently analyzed using a radiolabeled NF-κB probe. Nuclear proteins were reacted with the radiolabeled probe, run on a 5% polyacrylamide gel, and subjected to autoradiography. Specificity of protein binding for the NF-κB binding site was assayed by cold and nonspecific competition using the LPS treated sample in each experiment. All EMSA were duplicated at least once to verify results. Laser densitometry of NF-κB bands was done on autoradiographs to quantify NF-κB binding activity.

The human T lymphoid cell line Jurkat was transfected with a response element lacZ reporter in which transcription of the β-galactosidase gene is directed by the binding site for the NF-κB transcription factor. The cell line containing κB-Z is stimulated with calcium ionophore A23187 and phorbol ester PMA; this stimulation is inhibited by the immunosuppressive drug cyclosporin A. In the screening assay transfected κB-Z Jurkat cells (1×10⁶ cells/assay well) are incubated with 2 μM A23187, 20 ng/mL PMA and test compound or vehicle in the well of a microplate for at least 4 hours according to the procedure of M. J. Lenardo and D. Baltimore, NF-κB: a pleiotropic mediator of inducible and tissue specific gene control. Cell 58, 227-229, (1989). At the end of the incubation, the cells are spun down and resuspended in the buffer and FDG (fluorescein di-β-D-galactopyranoside) solution. The covered plates are further incubated in the dark for 16 hours at 25° C. The fluorescent product resulting from the end of reaction is read at 485/530 in a Cyto2300 fluorescence reader. Compounds were screened at 10 μM. The standard, cyclosporin A has an lC₅₀ of 5 nM in this assay.

                                      TABLE III                                    __________________________________________________________________________     The effect of various aci-reductones on Nuclear Factor-kappa B                   Percent Inhibition (%)                                                                                             (PERCENT INHIBITION)                       Example  NF-κB                                                           # Compound Name (10 μM)                                                   __________________________________________________________________________     2    5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone                                                  90                                         5 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-propyl-2(5H)-furanone 68                                                 6 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihy                                           droxy-5-(2-methylpropyl)-2(5H)-furan                                           one 59                                     7 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-phenyl-2(5H)-furanone 21                                                 8 3,4-Dihydroxy-5,5-diphenyl-2(5H)-                                           furanone 33                                9 3,4-Dihydroxy-5-(4-isobutylphenyl)-5-(1-propyl)-2(5H)-furanone 26                                                 10 3,4-Dihydroxy-5-(4-isobutylpheny                                           l)-5-phenyl-2(5H)-furanone 16                                                   11 (S)-(+)-5-[(1,1'-Biphenyl)-4-yl]                                           -3,4-dihydroxy-5-methyl-2(5H)-furano                                           ne 72                                      12 (R)-(-)-5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanon                                           e 56                                       13 (R)-(-)-3,4-Dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-fur                                           anone 49                                   14 (S)-(+)-3,4-Dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-fur                                           anone 60                                   24 3,4-Dihydroxy-5-[2-(4,5-diphenyl-1,3-oxazole-2-thio)ethyl]-2(5H)-fura                                           none 44                                    41 3,4-Dihydroxy-5-[2-(4-(4-fluorophenylmethyl)thiophene)-(3-butynyl)]-2                                           (5H)- 61; IC.sub.50 = 6 μM                                                    furanone                               __________________________________________________________________________

The ability of the compounds of formula I to inhibit the action of various inflammatory cytokines make them useful in a wide variety of therapeutic methods. Specifically, their ability to mediate or inhibit the actions of TNF-α makes these compounds useful in the treatment of various invasive diseases, infections, and inflammatory states. Particularly important is the inhibition of the large amount of TNF produced during serious bacterial infections, which can trigger a state of shock and tissue injury (septic shock syndrome).

A further important use of the compounds of formula I is to inhibit the TNF which is known to mediate cachexia produced during chronic disease states. Thus, these compounds are particularly useful in adjunctive therapy for AIDS and cancer patients to reduce and/or ameliorate the consequences of cachexia produced during these chronic disease states.

A further specific method of treatment for which the compounds of the instant invention are particularly useful is in the treatment of rheumatoid arthritis wherein increased amounts of the inflammatory cytokines, TNF-α and IL-1 are present. By virtue of their abilitv to mediate and/or inhibit the action of these cytokines, inflammation and the severity of the disease state can be reduced or eliminated.

The compounds of the instant invention can also be utilized in the treatment of multiple sclerosis (MS), Crohn's disease and ulcerative colitis by inhibiting and the activity of the inflammatory cytokines which underlie these disease states.

The compounds of the invention may be formulated in a conventional manner, optionally together with one or more other active ingredients, for administration by any convenient route for example of oral, intravenous or intramuscular administration.

Thus, according to another aspect, the invention provides a pharmaceutical composition comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or excipient.

For oral administration, the pharmaceutical composition may take the form of, for example, tablets, capsules, powders, solutions, syrups or suspensions prepared by conventional means with physiologically acceptable excipients.

The compounds may be formulated for intravenous or intramuscular administration in dry form for reconstitution before use, or as a sterile solution or suspension.

A proposed daily dose based on similar pharmacokinetic parameters to CHTA for administration to man is about 10 to 25 mg/kg, for example, 700 mg to 1 gm daily, which may be conveniently administered in 1 to 3 doses per day. The precise dose administered will, of course, depend on the age and condition of the patient.

The following examples are illustrative of the present invention.

EXAMPLES

General Methods. Unless otherwise noted all reagents were purchased from commercial suppliers and used as received. Melting points were determined in open capillaries with a Thomas-Hoover Uni-Melt Apparatus and are uncorrected. Nuclear magnetic resonance spectra were obtained with either an IBM-Bruker model NR/100 or Varian model 200 FT NMR spectrometer. Tetramethylsilane (TMS) in CDCl₃, DMSO-d₆, acetone-d₆, CD₃ OD or D₂ O was used as internal standard. Chemical shifts are reported on the δ scale with peak multiplicities: s, singlet; d, doublet; dd, doublet of doublets; ddd doublet of doublet of doublets; t, triplet; q, quartet, m, multiplet. Anhydrous solvents were purchased from Aldrich Chemical, Inc., Milwaukee, Wis. and used as such. Optical rotations were performed on a Perkin-Elmer model 241 polarimeter using a 10 cm, 1 mL cell. Elemental Analyses were performed by Quantitative Technologies, Inc., Whitehouse, N.J.

Preparation of Starting Materials Example A Ethyl 4-phenylbenzoylformate

A mixture of 77 g (500 mmol) of biphenyl and 68 mL (540 mmol) of ethyl oxalylchloride was dissolved in 300 mL of 1,2-dichloroethane and cooled with stirring to between 0° and 10° C. AlCl₃ (73 g, 550 mmol) was added at such a rate to maintain the reaction temperature below 15° C. The mixture was stirred at 10° C. for 1 hour and at 25° C. for 24 hours, then poured into 1000 mL of a ice cold 10% HCl solution. The aqueous suspension was extracted with 4×500 mL of ether and the combined ether extracts were washed with 100 mL of 10% HCl solution, 100 mL of brine, dried (MgSO₄) and concentrated to a yellow oil which was purified by chromatography over SiO₂ using initially acetone/hexanes (2/98) and increasing the polarity of the solvent to acetone/hexanes (10/90) upon elution of the nonpolar impurities to liberate 82 g (68% yield) of a yellow oil, which crystallized on standing.

Example B Ethyl 4-isobutylbenzoylformate

A mixture of 27 g (200 mmol) of isobutylbenzene and 24 mL (215 mmol) of ethyl oxalylchloride underwent Friedel-Crafts acylation reaction in an analogous fashion as described for the synthesis of ethyl 4-phenylbenzoylformate to yield 38 g (81% yield) of ethyl 4-isobutylbenzoylformate as a colorless oil.

Example C 3-Benzyloxy-4-hydroxy-5-(2-hydroxy)ethyl-2(5H)-furanone

A. A solution of 10 g (98 mmol) of α-hydroxy-γ-butyrolactone in 100 mL of anhydrous THF under argon was cooled to 0-5° C. with magnetic stirring. Addition of 14 mL (110 mmol) of trimethylsilyl chloride and 16 mL (115 mmol) of triethylamine immediately produced a white precipitate. The suspension was warmed to room temperature and stirred for 4 hours. The suspension was poured into a separatory funnel containing 100 mL of H₂ O and 500 mL of ether. The organic layer was washed with 50 mL of H₂ O, 50 mL of brine, dried (MgSO₄) and concentrated. Purification (Kugelrohr distillation) provided 14.7 g (90% yield) of α-trimethylsilyloxy-γ-butyrolactone bp 80-100° C. (8 mm Hg).

B. To a 500 mL 2-necked flask flame dried under argon and equipped with a magnetic stir bar, was added 200 mL of THF and 18.7 mL (89 mmol) of hexamethyldisilazide. The flask was cooled to -78° C. and 55.4 mL (89 mmol) of a 1.6M nBuLi solution in hexanes was added with stirring over 15 min. The light yellow solution was stirred for an additional 15 min and 16.7 g (86 mmol) of ethyl benzyloxyacetate was added over 5 min. The solution was stirred for 20 min at -78° C., and 14.7 g (84.4 mmol) of α-silyloxy-γ-butyrolactone was added via syringe. The reaction mixture was quenched after 30 minutes by pouring into a mixture of 100 mL of 10% aqueous HCl solution and 500 mL of ether. The aqueous layer was separated and washed with 2×100 mL of ether. The combined ether extracts were washed with 50 mL of brine. dried (MgSO₄) and concentrated leaving a yellow oil, which was dried in vacuo for 15 hours.

C. The yellow oil was placed under argon, diluted with 400 mL of MeOH, cooled to 0° C. with stirring and 11.7 g (85 mmol) of anhydrous K₂ CO₃ was added. After 30 minutes the suspension was concentrated to a volume of about 75 mL, diluted with 100 mL of H₂ O and 50 mL of saturated sodium bicarbonate solution, and washed with 2×100 mL of ether. The aqueous phase was acidified with 37% HCl solution to a pH near 1 and extracted with 10×150 mL of ether. The combined ether extracts were washed with 100 mL of brine, dried (MgSO₄) and concentrated to a yellow oil (18.7 g, 86%) which solidified upon standing. Recrystallization from benzene and hexanes provided 15.8 g, (75% yield) of 3-benzyloxy-4-hydroxy-5-(2-hydroxy)ethyl-2(5H)-furanone as a white solid: mp 98-99° C., ¹ H NMR (acetone-d₆) δ 7.46-7.27 (m, 5H), 5.06 (s, 2H), 4.83 (t, J=6.3 Hz, 1H), 3.85-3.69 (m, 2H), 2.05-1.95 (m, 1H), 1.89-1.76 (m, 1H). Anal Calcd for C₁₃ H₁₄ O₅ : C, 62.39; H, 5.64. Found: C, 62.51; H, 5.50.

Example D 3,4-Dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone

A mixture of 1.25 g (5 mmol) of 3-benzyloxy-4-hydroxy-5-(2-hydroxyethyl)-2(5H)-furanone, 15 mL of THF, 871 μL (5.0 mmol) of diisopropylethylamine and 631 μL (5.2 mmol) of benzyl bromide were combined under argon. The reaction mixture was warmed to reflux for 5 hours, and upon cooling, a suspension formed which was poured into 50 mL of 5% aqueous HCl solution and extracted with 100 mL of ether. The ether fraction was separated and sequentially washed with 30 mL of 5% aqueous HCl, 30 mL of H₂ O, 30 mL of saturated NAHCO₃ solution, 30 mL of H₂ O, 30 mL of brine, dried (MgSO₄) and concentrated to a colorless oil. Purification over silica gel using EtOAc/hexanes (2/3) provided 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone as a faint pink colored oil (1.0 g, 60% yield).

Example E 3-Benzyloxy-4-hydroxy-5-(2-iodoethyl)-2(5H)-furanone

To an oven dried 250 mL round bottom flask flushed with argon was added 5.8 g (22 mmol) of PPh₃, 1.5 g (22 mmol) of imidazole and 80 mL of ether/CH₃ CN (3/1). The mixture was cooled in an ice water bath with magnetic stirring and 5.6 g (22 mmol) of iodine was added in 4 equal portions with vigorous stirring. The resulting slurry was warmed at room temperature for 20 minutes, cooled to 0° C., and 5.0 g (20 mmol) of 3-benzyloxy-4-hydroxy-5-(2-hydroxyethyl)-2(5H)-furanone dissolved in 20 mL of CH₃ CN/ether (1/1) was added in one portion and the remainder was rinsed in with 5 mL of ether. The mixture was stirred at 0° C. for 10 minutes, then at room temperature for 30 minutes and quenched by pouring into 150 mL of 10% HCl solution and extracting with 500 mL of ether/hexanes (1/1). The aqueous layer was separated and extracted with 100 mL of ether. The combined organic fractions were washed with 50 mL of H₂ O and extracted with 5×50 mL of saturated NaHCO₃ solution. The combined bicarbonate extracts were washed with 50 mL of ether/hexanes (1/1), acidified to pH below 2 with 10% HCl solution and extracted with 3×200 mL of ether. The combined ether extracts were washed with 100 mL of brine, dried (MgSO₄) and concentrated to give 6.7 g, (93% yield) of 3-benzyloxy-4-hydroxy-5-(2-iodoethyl)-2(5H)-furanone as a white solid, which was not further purified: mp 100-104° C., ¹ H NMR (CDCl₃) δ 7.40-7.27 (m, 5H), 5.06, (dd, J=11.4 Hz, 2H), 4.69 (dd, J=3.4, 8.0 Hz, 1H), 3.06 (t, J=7.3 Hz, 2H), 2.41-2.29 (m, 1H), 2.02-1.90 (m, 1H); ¹³ C NMR (CDCl₃) δ 170.33, 160.61, 136.32, 128.77, 128.69, 128.58, 120.11, 75.76, 73.39, 35.77, -2.03; Anal Calcd for C₁₃ H₁₃ O₄ I: C, 43.35; H, 3.64. Found: C, 43.94; H, 3.69.

Example F 3,4-Dihydroxy-5-(2-iodoethyl)-2(5H)-furanone

To a dry flask flushed with argon was added 0.72 g (2.0 mmol) of 3-benzyloxy-4-hydroxy-5-(2-iodoethyl)-2(5H)-furanone and 10 mL of CH₂ Cl₂. The solution was cooled with stirring in an ice-water bath, and 0.38 mL (4.0 mmol) of acetic anhydride and 0.34 mL (4.2 mmol) of pyridine were added. The ice bath was removed and the solution was stirred for 1 hour. All volatile substances were removed in vacuo (2 h at 1 mm Hg, 25° C.). Argon was introduced to the reaction flask and the residue was taken up in 20 mL of dry CH₂ Cl₂, cooled to -78° C. and 5.2 mL (2.6 mmol) of 1.0M BCl₃ in CH₂ Cl₂ was added with stirring. The reaction mixture was kept at -78° C. for 1 hour and at room temperature for 30 minutes. The mixture was poured into 50 mL of brine and extracted with 3×30 mL of ether. The combined ether extracts were washed with 5 mL of H₂ O and extracted into saturated NaHCO₃ solution (3×15 mL). The bicarbonate fractions were pooled and washed with 15 mL of ether, acidified to pH 1 with 25% aqueous HCl solution, and extracted with 3×30 mL of ether. The ether extracts were combined and washed with 15 mL of brine, dried (MgSO₄) and concentrated to provide 360 mg (67% yield) of 3,4-dihydroxy-5-(2-iodoethyl)-2(5H)-furanone as a white crystalline solid: mp 150-151° C.; ¹ H NMR (acetone-d₆) δ 4.80 (dd, 1H, J=3.5, 8.0 Hz), 3.50-3.25 (m, 2H), 2.60-2.35 (m, 1H), 2.20-1.95 (m, 1H). Anal Calcd for C₆ H₇ O₄ I: C, 26.69; H, 2.61. Found: C, 26.54; H, 2.59.

Example G 3-Benzyloxy-5-(3-butyne)-4-hydroxy-2(5H)-furanone

To a flame-dried three-necked round bottom flask with magnetic stir bar, argon inlet, and septum containing 5.7 g (55.8 mmol) of 90% lithium acetylide ethylenediamine complex, was added 20 mL of HMPA. The suspension was stirred for 15 minutes at room temperature, cooled in an ice bath (acetone/CO₂) to between -5° C. and -10° C., and 6.7 g (18.6 mmol) of 3-benzyloxy-4-hydroxy-5-(2-iodoethyl)-2(5H)-furanone dissolved in 15 mL of HMPA was added over a two minute period. A dark brown-orange slurry formed and the temperature was maintained between 0° C. and -5° C. for 30 minutes. The mixture was quenched by the careful addition of 150 mL of 10% aqueous HCl solution, which was immediately extracted with 2×200 mL of ether. The combined ether extracts were washed with 2×50 mL of 5% aqueous HCl solution and extracted with 4×50 mL of NaHCO₃ solution. The combined bicarbonate extracts were washed with 50 mL of ether, acidified with 20% aqueous HCl solution to pH 1 and extracted with 3×150 mL of ether. The combined ether extracts were washed with 50 mL of brine, dried (MgSO₄) and concentrated leaving 4.1 g (85% crude yield) of 3-benzyloxy-5-(3-butyne)-4-hydroxy-2(5H)-furanone as a yellow solid. This material was used without further purification in subsequent steps: mp 85-88° C.; ¹ H NMR (CDCl₃) δ 7.38-7.26 (m, 5H), 5.06, (q, J_(ab) =11.6 Hz, 2H), 4.75 (dd, J=3.5, 8.1 Hz, 1H), 2.27-2.20 (m, 2H), 2.12-2.01 (m, 1H), 1.98 (t, J=2.6 Hz, 1H), 1.73-1.62 (m, 1H); ¹³ C NMR (CDCl₃) δ 169.93, 160.90, 136.39, 128.77, 128.73, 128.64, 120.13, 82.31, 74.30, 73.43, 69.71, 30.78, 13.72.

Example H 5-(3-Butyne)-3,4-dihydroxy-2(5H)-furanone

An oven dried 250 mL flask equipped with a magnetic stir bar was flushed with argon and charged with 2.6 g (10.0 mmol) of 3-benzyloxy-5-(3-butyne)-4-hydroxy-2(5H)-furanone and 50 mL of anhydrous CH₂ Cl₂. The solution was cooled in an ice bath to 5° C. with magnetic stirring and 1.9 mL (20.0 mmol) of acetic anhydride was added followed by 1.7 mL (21 mmol) of pyridine. The ice bath was removed after 1 hour, and the mixture was concentrated on a rotary evaporator and dried at 0.5 mm Hg at 25° C. for 12 hours. Argon was introduced followed by 100 mL of dry CH₂ Cl₂. The solution was cooled to -78° C. with stirring and 25 mL (25 mmol) of 1.0M BCl3 in CH₂ Cl₂ was added. The reaction mixture was allowed to gradually warn to 10° C. over a 2 hour period and maintained at 10° C. for 1 hour. The mixture was poured into 50 mL of brine and extracted with 4×100 mL of ether. The combined ether fractions were extracted with 3×25 mL of saturated NaHCO₃ solution. The combined bicarbonate extracts were washed with 25 mL of ether and acidified to pH 1 with aqueous HCl solution and extracted with 5×100 mL of ether. The combined ether washes were dried (MgSO₄) and filtered through 100 g of silica gel to remove a polar impurity using 1 L of ether as eluant. Removal of solvent in vacuo left 1.4 g (80% yield) of 5-(3-butyne)-3,4-dihydroxy-2(5H)-furanone as an off white solid: mp 124-128° C. dec.; ¹ H NMR (acetone-d₆) δ 4.79 (dd, J=3.4, 8.3 Hz, 1H), 2.42 (t, J=2.6 Hz, 1H), 2.37-2.30 (m, 2H), 2.20-2.09 (m, 1H), 1.81-1.67 (m, 1H); ¹³ C NMR (acetone-d₆) δ 170, 153.7, 119, 83.4, 74.7, 70.9, 32.4, 14.4; Anal Calcd for C₈ H₈ O₄ : C, 57.14; H, 4.79. Found: C, 57.04; H, 5.01.

Example I 2-(2Z-Hexenyl)iodobenzene

A dry 25 mL 2-necked flask equipped with a magnetic stir bar, argon inlet and septum was cooled to 0° C. and 3 mL of 1.0M BH₃ in THF was added. Cyclohexene, 607 μL (6 mmol) was added via syringe and the suspension stirred at 0-5° C. for 35 minutes. 2-Hexynyliodobenzene₅ (0.852 g, 3.0 mmol) was added to the reaction mixture dropwise over a 5 minute period, the ice bath was removed and the yellow reaction mixture stirred at room temperature for 1 hour. The solution was subsequently cooled in an ice bath, and 1.4 mL (25 mmol) of glacial AcOH was added. The mixture stirred at room temperature for 1 hour, was poured into 75 mL of H₂ O, and extracted with 3×30 mL of hexanes. The combined hexanes fractions were washed with 25 mL of H₂ O, 25 mL of saturated NaHCO₃ solution, 25 mL of H₂ O, 2×20 mL of brine, dried (MgSO₄) and concentrated to an oil (do not warm above 30° C. to avoid isomerization of the double bond). Purification over 40 g of silica gel using hexanes as eluant provided 670 mg (78%) of 2-(2Z-hexenyl)iodobenzene as a colorless oil: ¹ H NMR (CDCl₃) δ 7.82 (d, J=7.8 Hz, 1H), 7.30-7.20 (m, 2H), 6.91-6.86 (m, 1H), 5.62-5.46 (m, 2H), 3.47 (d, J=6.5 Hz, 2H), 2.17-2.10 (m, 2H), 1.49-1.37 (m, 2H), 0.94 (t, J=7.3 Hz, 3H); ¹³ C NMR (CDCl₃) δ 143.8, 139.3, 131.8, 129.2, 128.3, 127.7, 126.6, 100.8, 38.8, 29.6, 22.7, 13.9; Anal Calcd for C₁₂ H₁₅ I: C, 50.37; H, 5.28. Found: C, 49.97; H, 5.24.

Synthesis of Compounds of the Invention Example 1 3,4-Dihydroxy-5-methyl-5-phenyl-2(5H)-furanone

A. To a 2-necked flask flame dried under argon with septum and charged with a solution of 3.6 g (20 mmol) of ethyl benzoylformate in 50 mL of anhydrous THF at -30° C. was slowly added 7 mL (21 mmol) of a 3.0 M solution of methylmagnesium iodide. The reaction mixture was stirred at 0° C. for 45 minutes, then at room temperature for 30 minutes and again cooled to 0° C. Benzyloxyacetyl chloride (3.4 mL, 21 mmol) was added and the reaction mixture was stirred at room temperature for 1 hour, cooled to -78° C. and 33 mL of a 1.5M solution of LDA in THF was added with rapid stirring. The mixture was worked up after 1 hour by the addition of 100 mL of aqueous 10% HCl solution and 300 mL of ether. The layers were separated and the organic phase was washed with 50 mL aqueous 10% HCl solution, 30 mL of H₂ O, and extracted with 3×40 mL of saturated NaHCO₃ solution. The bicarbonate extracts were combined and washed with 40 mL of ether, acidified to pH 1 with 10% aqueous HCl solution, and extracted with 2×80 mL of ether. The organic fractions were combined, washed with 25 mL of H₂ O, 25 mL of brine, dried (MgSO₄), and concentrated leaving 1.2 g (20% yield) of 4-hydroxy-5-methyl-5-phenyl-3-phenylmethoxy-2-(5H)-furanone as a yellow oil.

B. The 4-hydroxy-5-methyl-5-phenyl-3-phenylmethoxy-2-(5H)-furanone (1.2 g) was subjected to hydrogenation over 100 mg of 5% Pd/BaSO₄ in 100 mL of MeOH at room temperature and under 30 psi H2. The reaction was monitored periodically by TLC analysis. The suspension was filtered through two #1 filter papers, concentrated to a white solid and recrystallized from MeOH/H₂ O to give 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone as a white crystalline material: mp 173-175° C. dec. ¹ H NMR (acetone-d₆) δ 7.53-7.36 (m, 5H), 1.84 (s, 3H). Anal Calcd for C₁₁ H₁₀ O₄ +0.125H₂ O): C, 63.38; H, 4.96. Found: C, 63.30; H, 4.96.

Example 2 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone

A. A total of 3.4 mL (10.2 mmol) of 3.0M methylmagnesium iodide in THF was added to a THF solution of 2.4 g (10 mmol) of ethyl 4-phenylbenzoylformate in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to give prior to hydrogenolysis, 1.1 g (30% yield) of 5-[(1,1'-biphenyl)-4-yl]-3-phenylmethoxy-4-hydroxy-5-methyl-2(5H)-furanone as a white granular solid: m.p. 182-183° C. (benzene/hexanes) ¹ H NMR (CDCl₃) δ 7.56-7.26 (m, 14H), 5.10 (ab quartet, 2H, J=11.4 Hz), 1.79 (s, 3H). ¹³ C NMR (CDCl₃) δ 168.5, 163.8, 141.5, 140.3, 137.0, 136.3, 129.0, 128.8, 128.8, 128.8, 127.6, 127.2, 127.1, 125.6, 119.0, 81.1, 73.5, 24.3. Anal Calcd for C₂₄ H₂₀ O₄ : C, 77.40; H, 5.41. Found: C, 77.99; H, 5.61.

B. Hydrogenolysis of 500 mg of the 5-[(1,1'-biphenyl)-4-yl]-3-phenylmethoxy-4-hydroxy-5-methyl-2(5H)-furanone was performed in a similar manner as described in the synthesis of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provided 240 mg (63% yield) of 5-[(1,1'-biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone as a white powder: mp 206-212° C. dec. (MeOH/H₂ O), ¹ H NMR (acetone-d₆) δ 7.69-7.33 (m, 9H), 1.88 (s, 3H). ¹³ C NMR (acetone-d₆) δ 169.5, 157.1, 141.6, 141.0, 139.8, 129.6, 128.3, 127.6, 127.6, 126.6, 117.9, 81.2, 24.5. Anal Calcd for C₁₇ H₁₄ O₄ : C, 72.33; H, 5.00. Found: C, 72.07; H, 5.14.

Example 3 3,4-Dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-furanone

A. A total of 3.4 mL (10.2 mmol) of 3.0M methylmagnesium iodide in THF was added to a THF solution of 2.34 g (10 mmol) of ethyl 4-isobutylbenzoylformate in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to give prior to hydrogenolysis 4-hydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-3-phenylmethoxy-2(5H)-furanone in 45% yield as a yellow oil. ¹ H NMR (CDCl₃) δ 7.37-7.02 (m, 9H), 5.01 (s, 2H), 2.42 (d, 2H, J=7.2 Hz), 1.86-1.77 (m, 1H), 1.72 (s, 3H), 0.87 (d, 6H, J=6.6 Hz). ¹³ C NMR (CDCl₃) δ 170.0, 165.1, 142.1, 136.3, 135.2, 129.2, 128.9, 128.6, 127.2, 125.0, 118.6, 81.7, 73.5, 45.0, 30.2, 24.1, 22.4. Anal Calcd for C₂₂ H₂₄ O₄ +0.5 H₂ O: C, 73.11; H, 6.97. Found: C, 72.92; H, 6.87.

B. Hydrogenolysis of 800 mg (2.3 mmol) of 4-hydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-3-phenylmethoxy-2(5H)-furanone was performed in a similar manner as described in the preparation of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provided 500 mg (84% yield) of 3,4-dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-furanone as a light yellow crystalline material: mp 135-150° C. dec. ¹ H NMR (acetone-d₆) δ 7.40-7.17 (m, 4H), 2.46 (d, 2H, J=7.1 Hz), 1.87-1.82 (m, 1H), 1.82 (s, 3H), 0.87 (d, 6H, J=6.6 Hz). ¹³ C NMR (acetone-d₆) δ 169.5, 157.2, 142.4, 138.0, 129.8, 125.9, 117.9, 81.3, 45.3, 30.8, 24.5, 22.5. Anal Calcd for C₁₅ H₁₈ O₄ +0.25 H₂ O: C, 67.53; H, 6.99. Found: C, 67.78; H, 7.09.

Example 4 5-(4-Chlorophenyl)-3,4-dihydroxy-5-methyl-2(5H)-furanone

A. A total of 3.4 mL (10.2 mmol) of 3.0M methylmagnesium iodide was added to a solution of 2.34 g (10 mmol) of ethyl 4-chlorobenzoylformate in THF in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to give prior to hydrogenolysis 1.3 g (40% yield) of 5-(4-chlorophenyl)-4-hydroxy-5-methyl-3-phenylmethoxy-2(5H)-furanone as a yellow oil: ¹ H NMR (CDCl₃) δ 7.37-7.21 (m, 9H), 5.10 (s, 2H), 1.73 (s, 3H).

B. Hydrogenolysis of 330 mg of 5-(4-chlorophenyl)-4-hydroxy-5-methyl-3-phenylmethoxy-2(5H)-furanone was performed in a similar manner as described in the preparation of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provided 110 mg (46% yield) of 5-(4-chlorophenyl)-3,4-dihydroxy-5-methyl-2(5H)-furanone a light tan solid: mp 154-155° C. dec.(benzene/hexanes) ¹ H NMR (acetone-d₆) δ 7.52-7.34 (m, 4H), 1.82 (s, 3H). ¹³ C NMR (acetone-d₆) δ 169.0, 156.6, 139.8, 134.3, 129.2, 127.8, 117.9, 80.8, 24.6. Anal Calcd for C₁₁ H₉ ClO₄ : C, 54.90; H, 3.77. Found: C, 54.74; H, 4.08.

Example 5 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-propyl-2(5H)-furanone

A. A total of 5.2 mL (10.4 mmol) of 2.0M n-propylmagnesium bromide was added to a solution of 2.4 g (10 mmol) of ethyl 4-phenylbenzoylformate in THF in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to give prior to hydrogenolysis 0.30 g (8% yield) of 5-[(1,1'-biphenyl)-4-yl]-4-hydroxy-3-phenylmethoxy-5-propyl-2(5H)-furanone as an off white solid after crystallization from CHCl₃ and hexanes.

B. Hydrogenolysis of 250 mg of 5-[(1,1'-biphenyl)-4-yl]-4-hydroxy-3-phenylmethoxy-5-propyl-2(5H)-furanone was performed in a similar manner as described in the preparation of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provided 100 mg (52% yield) of a white powder: mp 203-204° C. dec.(acetone/CHCl₃ /hexanes). ¹ H NMR (acetone-d₆) δ 7.65-7.40 (m, 9H), 2.25-1.95 (m, 2H), 1.45-1.10 (m, 2H), 0.95 (t, J=6.9 Hz, 3H). Anal Calcd for C₁₉ H₁₈ O₄ +0.125 H₂ O: C, 73.01; H, 5.88. Found: C, 72.99; H, 5.86.

Example 6 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-(2-methylpropyl)-2(5H)-furanone

A. A total of 5.2 mL (10.4 mmol) of 2.0M isobutylmagnesium bromide was added to a solution of 2.4 g (10 mmol) of ethyl 4-phenylbenzoylformate in THF in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to give prior to hydrogenolysis 0.35 g (8% yield) of 5-[(1,1'-biphenyl)-4-yl]-4-hydroxy-3-phenylmethoxy-5-(2-methylpropyl)-2(5H)-furanone as an off white solid after crystallization from CHCl₃ and hexanes.

B. Hydrogenolysis of 350 mg of 5-[(1,1'-biphenyl)-4-yl]-4-hydroxy-3-phenylmethoxy-5-(2-methylpropyl)-2(5H)-furanone was performed in a similar manner as described in the preparation of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provide 190 mg (69% yield) of a white powder: mp 198-199° C. dec.(CHCl₃ /hexanes). ¹ H NMR (acetone-d₆) δ 7.73-7.34 (m, 9H), 2.44-2.28 (m, 1H), 1.50-0.80 (m, 8H). ¹³ C NMR (acetone-d₆) δ 169.21, 155.47, 140.81, 139.57, 129.17, 127.73, 127.18, 127.08, 126.04, 118.47, 86.01, 40.66, 23.72, 12.11, 11.87. Anal Calcd for C₂₀ H₂₀ O₄ +0.125 H₂ O: C, 73.55; H, 6.25. Found: C, 73.25; H, 6.36.

Example 7 5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-phenyl-2(5H)-furanone

A. A total of 3.4 mL (10.2 mmol) of 3.0M phenylmagnesium bromide was added to a solution of 2.4 g (10 mmol) of ethyl 4-phenylbenzoylformate in THF in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to give prior to hydrogenolysis 0.88 g (20% yield) of 5-[(1,1'-biphenyl)-4-yl]-4-hydroxy-3-phenylmethoxy-5-phenyl-2(5H)-furanone as an off white solid: mp 190-195° C. (CHCl₃ /hexanes).

B. Hydrogenolysis of 500 mg of 5-[(1,1'-biphenyl)-4-yl]-4-hydroxy-3-phenylmethoxy-5-phenyl-2(5H)-furanone was performed in a similar manner as described in the preparation of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provide 150 mg (38% yield) of 5-[(1,1'-biphenyl)-4-yl]-3,4-dihydroxy-5-phenyl-2(5H)-furanone as colorless needles: mp 188-191° C. dec.(CHCl₃ /hexanes). ¹ H NMR (acetone-d₆) δ 7.75-7.36 (m, 14H). ¹³ C NMR (acetone-d₆) δ 168.34, 154.84, 141.50, 140.66, 140.30, 139.42, 129.18, 128.74, 128.59, 127.92, 127.40, 127.25, 127.07, 119.45, 84.59. Anal Calcd for C₂₂ H₁₆ O₄ : C, 76.73; H, 4.68. Found: C, 76.44; H, 4.50.

Example 8 3,4-Dihydroxy-5,5-diphenyl-2(5H)-furanone

A. A total of 3.5 mL (10.5 mmol) of 3.0M phenylmagnesium bromide was added to a solution of 1.6 mL (10 mmol) of ethyl benzoylformate in THF in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to give 5,5-diphenyl-4-hydroxy-3-phenylmethoxy-2(5H)-furanone as an oil, which was purified over SiO₂ using acetone/hexanes (3/7).

B. Hydrogenolysis of 5,5-diphenyl-4-hydroxy-3-phenylmethoxy-2(5H)-furanone was performed in a similar manner as described in the preparation of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provide 150 mg (5.6% overall yield) of 3,4-dihydroxy-5,5-diphenyl-2(5H)-furanone as colorless needles: mp 192-193° C. dec.(CHCl₃ /hexanes). ¹ H NMR (acetone-d₆) δ 7.41 (s, 10H). ¹³ C NMR (acetone-d₆) δ 168.38, 154.92, 140.44, 128.72, 128.58, 127.43, 119.46, 84.74. Anal Calcd for C₁₆ H₁₂ O₄ +0.25 H₂ O C, 70.46; H, 4.62. Found: C, 70.42; H, 4.52.

Example 9 3,4-Dihydroxy-5-(4-isobutylphenyl)-5-(1-propyl)-2(5H)-furanone

A. A total of 5.2 mL (10.4 mmol) of 2.0M 1-propylmagnesium bromide was added to a solution of 2.3 g (10 mmol) of ethyl 4-isobutylbenzoylformate in THF in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provide 4-hydroxy-5-(4-isobutylphenyl)-3-phenylmethoxy-5-(1-propyl)-2(5H)-furanone as an oil, which was purified over SiO₂ using acetone/hexanes (1/4).

B. Hydrogenolysis of 4-hydroxy-5-(4-isobutylphenyl)-3-phenylmethoxy-5-(1 -propyl)-2(5H)-furanone was performed in a similar manner as described in the preparation of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provide 200 mg (6.9% yield) of 3,4-dihydroxy-5-(4-isobutylphenyl)-5-(1-propyl)-2(5H)-furanone as an oil, which was purified by preparative TLC using hexanes/acetone/acetic acid (70/29/1) as eluant: ¹ H NMR (acetone-d₆) δ 7.48-7.13 (m, 4H), 2.47 (d, J=10.3 Hz, 2H), 2.10-1.66 (m, 1H), 1.29-0.85 (m, 13H). ¹³ C NMR (acetone-d₆) δ 169.20, 155.54, 141.58, 137.91, 129.24, 125.32, 118.25, 83.37, 45.02, 39.60, 30.26, 22.03, 16.84, 13.63. Anal Calcd for C₁₇ H₂₂ O₄ : C, 70.32; H, 7.64. Found: C, 70.01; H, 7.61.

Example 10 3,4-Dihydroxy-5-(4-isobutylphenyl)-5-phenyl-2(5H)-furanone

A. A total of 3.5 mL (10.5 mmol) of 3.0M phenylmagnesium bromide was added to a solution of 2.3 g (10 mmol) of ethyl 4-isobutylbenzoylformate in THF in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provide an oil, which was purified over 400 g of SiO₂ by eluting with 5000 mL of CHCl₃, 500 mL of EtOH/CHCl₃ (3/97) and 500 mL of EtOH/CHCl₃ (8/92) to provide 1.2 g (29% yield) of 4-hydroxy-5-(4-isobutylphenyl)-5-phenyl-3-phenylmethoxy-2(5H)-furanone as a tan powder recrystallized from CHCl₃ and hexanes.

B. Hydrogenolysis of 500 mg (1.2 mmol) of 4-hydroxy-5-(4-isobutylphenyl)-5-phenyl-3-phenylmethoxy-2(5H)-furanone was performed in a similar manner as described in the preparation of 3,4-dihydroxy-5-methyl-5-phenyl-2(5H)-furanone to provide 200 mg (51% yield) of 3,4-dihydroxy-5-(4-isobutylphenyl)-5-phenyl-2(5H)-furanone as a white powder: mp 138-139° C. (CHCl₃ /hexanes). ¹ H NMR (acetone-d₆) δ 7.40-7.15 (m, 9H), 2.49 (d, J=7.1 Hz, 2H), 1.94-1.74 (m, 1H), 0.89 (d, J=6.5 Hz, 6H). Anal Calcd for C₂₀ H₂₀ O₄ : C, 74.1; H, 6.2. Found: C, 73.7; H, 6.3.

Example 11 (S)-(+)-5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone

A. To a flame dried 500 mL flask flushed with N₂, was added 24 g (100 mmol) of ethyl 4-phenylbenzoylformate and 300 mL of anhydrous THF. The solution was cooled with stirring to -25° C. and 37 mL (110 mmol) of a 3.0M solution of methylmagnesium iodide was added at a rate to maintain the reaction temperature below -10° C. The reaction progress was monitored by TLC and upon disappearance of starting material, 100 mL of saturated NH₄ Cl solution and 200 mL of ether were added. The organic layer was separated and washed with 2×50 mL of brine, dried (MgSO₄) and concentrated leaving racemic ethyl 2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionate as an oil.

B. The crude ethyl 2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionate was saponified by treating with 100 mL of ethanol and 100 mL of 4.0M NaOH solution. The suspension was stirred for 3 hours, after which a clear solution formed The solution was concentrated, diluted with 150 mL of H₂ O, washed with 2×50 mL of ether, and acidified to pH 1 with 10% HCl solution. The aqueous phase was extracted with 3×100 mL portions of ether and the combined ether extracts were washed with 50 mL of H₂ O, 50 mL of brine, dried (MgSO₄) and concentrated leaving 18.3 g (72% yield) of racemic 2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionic acid as a white solid after was recrystallization from CHCl₃ and hexanes.

C. Racemic 2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionic acid 12.1 g (50 mmol) was resolved by dissolving in 225 mL of a 2:2:1 mixture of isopropanol:benzene:hexanes. The solution was warmed to reflux and 6.9 g (50 mmol) of (R)-(-)-phenylglycinol was added in one portion. The mixture was allowed to cool slowly over 15 hours during which white crystals formed, which were isolated by filtration and washed with several small portions of isopropanol. The isolated white solid was recrystallized four additional times from isopropanol until a constant melting point of 189.5-191° C. was observed, leaving 4.3 g (45.3% yield for the resolution) of diastereomerically pure (S)-(+)-2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionate (R)-(-)-phenylglycinol salt.

D. Diastereomerically pure (S)-(+)-2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionate (R)-(-)-phenylglycinol salt (1.9 g, 5 mmol) was added to a separatory funnel containing 70 mL of 15% aqueous HCl solution and 150 mL of ether. The suspension was shaken until completely solvated, and the aqueous layer was separated. The ether portion was washed with 2×50 mL of 15% aqueous HCl solution, 50 mL of H₂ O, 50 mL of brine, dried (MgSO₄) and filtered into a 500 mL flask. The ether solution was cooled in an ice bath and a freshly prepared etheral solution of diazomethane was added with stirring until the yellow color of the reagent persisted. The solution was concentrated leaving 1.3 g (99%) of methyl (S)-(+)-2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionate as a white crystalline material.

E. In a dry flask under argon, were mixed 1.3 g (5 mmol) of methyl (S)-(+)-2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionate, 1.7 mL (10 mmol) of 95% benzyloxyacetyl chloride and 6.1 mL of pyridine. The reaction stirred for 48 hours and was quenched by pouring into 100 mL of 10% aqueous HCl and 200 mL of ether. The ether fraction was separated and washed with 50 mL of 10% aqueous HCl, 50 mL of H₂ O, 2×50 mL of NaHCO₃ solution, 50 mL of H₂ O, 50 mL of brine, dried (MgSO₄) and concentrated. The product was purified over 250 g of SiO₂ using initially EtOAc/hexanes (1/9) followed by EtOAc/hexanes (1.5/8.5) as eluant to yield 1.5 g (80% yield) of methyl (S)-(+)-2-[(1,1'-biphenyl)-4-yl]-2-(2-phenylmethoxyacetoyl)oxypropionate.

F. (S)-(+)-2-[(1,1'-Biphenyl)-4-yl]-2-(2-phenylmethoxyacetoyl)oxypropionate (1.5 g, 4 mmol) was dissolved in 10 mL of anhydrous THF and added to 33 mL of a 0.3M solution of LiHMDA in THF at -78° C. The light yellow solution stirred for 45 minutes and was quenched by the addition of 30 mL of 10% aqueous HCl solution. The mixture was taken into 200 mL of ether and washed with 30 mL of 10% aqueous HCl solution, 30 mL of H₂ O, 30 mL of brine, dried (MgSO₄) and concentrated. The resultant oil was taken up in 50 mL of ether and extracted with 4×30 mL of saturated NaHCO₃ solution. The combined NaHCO₃ fractions were washed with 25 mL of ether, acidified to pH below 1 with 10% aqueous HCl solution and extracted with 2×100 mL of ether. The combined ether extracts were washed with 25 mL of H₂ O, 25 mL of brine, dried (MgSO₄) and concentrated to give (S)-(+)-5-[(1,1'-biphenyl)-4-yl]-4-hydroxy-5-methyl-3-phenylmethoxy-2(5H)-furanone.

G. The (S)-(+)-5-[(1,1'-biphenyl)-4-yl]-4-hydroxy-5-methyl-3-phenylmethoxy-2(5H)-furanone was subjected to hydrogenation over 100 mg of 5% Pd/BaSO₄ in 100 mL of MeOH at room temperature under 30 psi of H₂. The reaction was monitored periodically by TLC analysis. Upon reaction completion, the suspension was filtered through two #1 filter papers, concentrated and recrystallized from CHCl₃ and hexanes to provide 300 mg (20% overall yield from methyl (S)-(+)-2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionate) of (S)-(+)-5-[(1,1'-biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone as a light weight white crystalline material: mp 204-206° C. dec.; [α]²⁵ _(D) +121° (c=0.66; MeOH); ¹ H NMR (acetone-d₆) δ 7.72-7.41 (m, 9H), 1.89 (s, 3H). Anal Calcd for C₁₇ H₁₄ O₄ +0.75 H₂ O: C, 69.03; H, 5.28. Found: C, 68.69; H, 4.95.

Example 12 (R)-(-)-5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone

A. The combined filtrates from the resolution of racemic 2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionic acid with (R)-(-)-phenylglycinol (example 11, section C) were concentrated to a thick brown paste and partitioned between 100 mL of 20% HCl solution and 400 mL of ether. The aqueous phase was separated and the ether layer was subsequently washed with 4×30 mL of 20% HCl solution, 50 mL of brine, dried (MgSO₄) and concentrated. A total of 8.5 g (35 mmol) of 2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionic acid was recovered and dissolved in 300 mL of isopropanol by warming to reflux and 4.5 g (35 mmol) of (S)-(+)-phenylglycinol was added. The diastereomeric salts were allowed to crystallize at 25° C. over a period of 72 hours and isolated by filtration and washed with 2×40 mL of isopropanol to provide 6.7 g of light brown crystals. Two subsequent recrystallizations from isopropanol provided 3.6 g of the diastereomerically pure salt of (R)-(-)-2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionic acid with (S)-(+)-phenylglycinol.

B. (R)-(-)-5-[(1,1'-Biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone was prepared in an analogous manner as described for (S)-(+)-5-[(1,1'-biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone starting with 1.9 g (5.0 mmol) of the diastereomerically pure salt of (R)-(-)-2-[(1,1'-biphenyl)-4-yl]-2-hydroxypropionic acid and (S)-(+)-phenylglycinol to provide 280 mg (19% yield) of(R)-(-)-5-[(1,1'-biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone as a white crystalline material: mp 197-199° C. dec. (CHCl₃ /hexanes); [α]²⁵ _(D) -182° (c=1.42; MeOH); ¹ H NMR (acetone-d₆) δ 7.65-7.41 (m, 9H), 1.89 (s, 3H). Anal Calcd for C₁₇ H₁₄ O₄ +0.25 H₂ O: C, 71.20; H, 5.10. Found: C, 71.19; H, 4.74.

Example 13 (R)-(-)-3,4-Dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-furanone

(R)-(-)-3,4-Dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-furanone was synthesized in an analogous manner used for the production of (S)-(+)-5-[(1,1'-biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone starting with ethyl 4-isobutylbenzoylformate. (R)-(-)-Phenylglycinol was used to resolve the methyl (R)-(-)-2-(4-isobutylphenyl)propionate enantiomer, of which 1.2 g, (5 mmol) was converted into 190 mg (15% yield) of (R)-(-)-3,4-dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-furanone as a white crystalline material: mp 180-181° C. dec. (CHCl₃ /hexanes); [α]²⁵ _(D) -137° (c=1.27; MeOH); ¹ H NMR (acetone-d₆) δ 7.44-7.14 (m, 4H), 2.48 (d, 2H, J=7.1 Hz), 1.87-1.82 (m, 1H), 1.83 (s, 3H), 0.88 (d, 6H, J=6.5 Hz). Anal Calcd for C₁₅ H₁₈ O₄ : C, 68.68; H, 6.92. Found: C, 68.52; H, 7.01.

Example 14 (S)-(+)-3,4-Dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-furanone

(S)-(+)-3,4-Dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-furanone was synthesized in an analogous manner used for the production of(R)-(-)-5-[(1,1'-biphenyl)-4-yl]-3,4-dihydroxy-5-methyl-2(5H)-furanone starting with ethyl 4-isobutylbenzoylformate. (S)-(+)-Phenylglycinol was used to resolve the methyl (S)-(+)-2-(4-isobutylphenyl)propionate enantiomer, of which 1.2 g (5 mmol) was converted into 250 mg (19% yield) of (S)-(+)-3,4-dihydroxy-5-methyl-5-[4-(2-methylpropyl)phenyl]-2(5H)-furanone as a white crystalline material: mp 175-177° C. dec. (CHCl₃ /hexanes); [α]²⁵ _(D) +132° (c=1.55; MeOH) ¹ H NMR (acetone-d₆) δ 7.44-7.14 (m, 4H), 2.48 (d, 2H, J=7.1 Hz), 1.87-1.82 (m, 1H), 1.83 (s, 3H), 0.88 (d, 6H, J=6.5 Hz). Anal Calcd for C₁₅ H₁₈ O₄ : C, 68.68; H, 6.92. Found: C, 68.08; H, 6.90.

Example 15 3,4-Dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone

A. A mixture consisting of 340 mg (1.0 mmol) of 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone, 320 mg (1.3 mmol) of triphenylphosphine and 225 mg (1.2 mmol) of 4-phenoxyphenol was dissolved in 8 mL of anhydrous THF under argon. Diisopropyl azodicarboxylate (276 μL 1.4 mmol) was added to the solution dropwise with stirring at 25° C. After 36 hours the reaction mixture was poured into 30 mL of H₂ O and extracted with two 30 mL portions of ether. The combined ether fractions were washed with 25 mL of saturated NaHCO₃ solution, 25 mL of H₂ O, 25 mL of aqueous 10% HCl solution, 25 mL of H₂ O, 25 mL of brine, dried (MgSO₄) and concentrated to an oil. The product was purified over silica gel using EtOAc/hexanes (2/3) as eluant to provide 3,4-dibenzyloxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone as an oil.

B. The 3,4-dibenzvloxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone was hydrogenated in 50 mL of MeOH over 50 mg of 5% Pd/BaSO₄ under 30 psi H₂. After completion of the reaction, as determined by TLC analysis, the suspension was filtered through celite, washed with three 10 mL portions of MeOH and concentrated to a white solid. Trituration with ether and hexanes provided 150 mg (44% yield) of 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone as a white powder: mp 125-127° C., ¹ H NMR (acetone-d₆) δ 7.42-7.28 (m, 2H), 7.12-6.88 (m, 7H), 4.95 (dd, 1H), 4.17 (q_(ab), 2H), 2.55-2.36 (m, 1H), 2.05-1.87 (m, 1H); ¹³ C NMR (acetone-d₆) δ 169.41, 158.91, 155.57, 153.39, 150.61, 129.98, 122.73, 120.94, 117.71, 116.32, 115.99, 72.43, 63.97, 32.43; Anal Calcd for C₁₈ H₁₆ O₆ +0.5 H₂ O; C, 64.12; H, 5.04: Found C, 64.28; H, 5.04.

Example 16 3,4-Dihydroxy-5-[2-(flavone-6-oxy)ethyl]-2(5H)-furanone

Mitsunoble coupling of 0.33 g (1.4 mmol) of 6-hydroxyflavone with 0.40 g (1.17 mmol) of 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone and subsequent benzyl group deprotection by hydrogenation were performed in a similar manner as described in the synthesis of 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone to provide 3,4-dihydroxy-5-[2-(flavone-6-oxy)ethyl]-2(5H)-furanone as a tan solid: mp 200-220° C. dec. (acetone/hexanes), ¹ H NMR (DMSO-d₆) δ 8.13-7.36 (m, 8H), 7.01 (s, 1H), 4.92 (dd, 1H), 4.17 (t, 2H), 2.47-2.27 (m, 1H), 1.98-1.85 (m, 1H). ¹³ C NMR (DMSO-d₆) δ 177.23, 170.22, 162.71, 156.02, 155.36, 150.80, 132.06, 131.51, 129.42, 126.59, 124.31, 123.85, 120.49, 117.44, 106.43, 105.85, 72.24, 64.20, 31.71. Anal Calcd for C₂₁ H₁₆ O₇ +0.25 H₂ O: C, 65.55; H, 4.44. Found: C, 65.59; H, 4.49.

Example 17 5-[2-(Dibenzofuran-2-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone

Mitsunoble coupling of 0.22 g (1.2 mmol) of 2-hydroxydibenzofuran with 0.34 g (1.0 mmol) of 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone and subsequent benzyl group deprotection by hydrogenation were performed in a similar manner as described in the synthesis of 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone to provide 40 mg (10% yield) of 5-[2-(dibenzofuran-2-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone a white solid.: mp 191-192° C. (ether/hexanes), ¹ H NMR (acetone-d₆) δ 8.23-8.18 (m, 1H), 7.83-7.44 (m, 5H), 7.28-7.23 (m, 1H), 5.12 (dd, J=5.3, 8.7 Hz, 1H), 4.42 (dd, J=2.6, 4.7 Hz, 2H), 2.69-2.59 (m, 1H), 2.21-2.08 (m, 1H). ¹³ C NMR (acetone-d₆) δ 169.68, 157.31, 155.75, 153.70, 151.31, 127.76, 125.05, 124.83, 123.07, 121.34, 118.46, 116.42, 112.39, 111.90, 105.40, 72.72, 64.57, 32.64. Anal Calcd for C₁₈ H₁₄ O₆ +0.25 H₂ O: C, 65.36; H, 4.57. Found: C, 65.52; H, 4.23.

Example 18 3,4-Dihydroxy-5-[2-(1-naphthoxy)ethyl]-2(5H)-furanone

Mitsunoble coupling of 0.17 g (1.2 mmol) of 1-naphthol with 0.34 g (1.0 mmol) of 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone and subsequent benzyl group deprotection by hydrogenation were performed in a similar manner as described in the synthesis of 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone to provide 75 mg (26% yield) of 3,4-dihydroxy-5-[2-(1-naphthoxy)ethyl]-2(5H)-furanone as colorless cubes: mp 163-164° C. (ether/hexanes) ¹ H NMR (acetone-d₆) δ 8.38-8.25 (m, 1H), 7.92-7.79 (m, 1H), 7.60-7.34 (m, 4H), 7.05-6.93 (m, 1H), 5.11 (dd, J=5.3, 8.7 Hz, 1H), 4.39 (dd, J=2.6, 4.7 Hz, 2H), 2.75-2.52 (m, 1H), 2.25-2.05 (m, 1H). ¹³ C NMR (acetone-d₆) δ 169.62, 154.92, 153.61, 135.13, 127.83, 126.78, 126.50, 125.92, 125.05, 122.41, 120.66, 118.53, 105.28, 72.85, 63.93, 32.58. Anal Calcd for C₁₆ H₁₄ O₅ : C, 67.11; H, 4.89. Found: C, 66.70; H, 4.88.

Example 19 3,4-Dihydroxy-5-[2-(1,8-naphthalimide)-N-ethyl]-2(5H)-furanone

Mitsunoble coupling of 0.24 g (1.2 mmol) of 1,8-naphthalimide with 0.34 g (1.0 mmol) of 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone and subsequent benzyl group deprotection by hydrogenation were performed in a similar manner as described in the synthesis of 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone to provide 150 mg (45% yield) of 3,4-dihydroxy-5-[2-(1,8-naphthalimide)-N-ethyl]-2(5H)-furanone as a white powder: mp 235-250° C. dec. (acetone/hexanes), ¹ H NMR (DMSO-d₆) δ 8.62-8.35 (m, 4H), 7.92-7.82 (m, 2H), 4.82 (dd, J=5.3, 8.7 Hz, 1H), 4.19 (t, J=4.2 Hz, 2H), 2.32-2.16 (m, 1H), 1.90-1.75 (m, 1H). ¹³ C NMR (DMSO-d₆) δ 170.29, 163.72, 154.91, 134.56, 131.52, 130.96, 127.60, 127.45, 122.29, 117.46, 73.64, 36.03, 30.58. Anal Calcd for C₁₈ H₁₃ NO₆ : C, 63.71; H, 3.86; N, 4.12. Found: C, 63.84; H, 3.83; N, 4.00.

Example 20 3,4-Dihydroxy-5-[2-(1,8-naphthosultam)-N-ethyl]-2(5H)-furanone

Mitsunoble coupling of 0.28 g (1.3 mmol) of 1,8-naphthosultarn with 0.3⁷ g (1.1 mmol) of 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone and subsequent benzyl group deprotection by hydrogenation were performed in a similar manner as described in the synthesis of 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone to provide 100 mg (29% yield) of 3,4-dihydroxy-5-[2-(1,8-naphthosultam)-N-ethyl]-2(5H)-furanone as a light yellow powder: mp 85-95° C. dec. (acetone/hexanes), ¹ H NMR (acetone-d₆) δ 8.29-7.55 (m, 5H), 7.12-7.01 (m, 1H), 4.97 (dd, J=4.9, 8.7 Hz, 1H), 4.10 (t, J=4.2 Hz, 2H), 2.72-2.50 (m, 1H), 2.18-1.95 (m, 1H). ¹³ C NMR (acetone-d₆) δ 169.28, 152.93, 136.42, 131.65, 131.10, 130.84, 130.00, 128.82, 120.03, 119.10, 118.60, 118.42, 103.71, 73.01, 37.72, 31.45. Anal Calcd for C₁₆ H₁₃ NO₆ S+1H₂ O: C, 52.60; H, 4.14; N, 3.83. Found: C, 52.62; H, 3.86; N, 3.56.

Example 21 3,4-Dihydroxy-5-[2-(diphenylmethane-2-oxy)ethyl]-2(5H)-furanone

Mitsunoble coupling of 0.28 g (1.3 mmol) of 2-hydroxy diphenylmethane with 0.37 g (1.1 mmol) of 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone and subsequent benzyl group deprotection by hydrogenation were performed in a similar manner as described in the synthesis of 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone to provide 140 mg (43% yield) of 3,4-dihydroxy-5-[2-(diphenylmethane-2-oxy)ethyl]-2(5H)-furanone as a white powder, which was purified by trituration with ether and hexanes: ¹ H NMR (acetone-d₆) δ 7.33-6.82 (m, 9H), 4.78 (dd, J=5.3, 8.7 Hz, 1H), 4.19 (dd, J=2.6, 4.7 Hz, 2H), 3.96 (s, 2H); 2.57-2.36 (m, 1H), 2.10-1.82 (m, 1H). Anal Calcd for C₁₉ H₁₈ O₅ : C, 69.9; H, 5.6. Found: C, 69.75; H, 5.52.

Example 22 5-[2-((1,1'-Biphenyl)-4-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone

Mitsunoble coupling of 0.20 g (1.2 mmol) of 4-hydroxy-1,1'-biphenyl with 0.34 g (1.0 mmol) of 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone and subsequent benzyl group deprotection by hydrogenation were performed in a similar manner as described in the synthesis of 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone to provide 100 mg (32% yield) of 5-[2-((1,1'-biphenyl)-4-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone as a white powder after trituration with ether and hexanes: ¹ H NMR (acetone-d₆) δ 7.71-7.02 (m, 9H), 4.97 (dd, J=4.9, 8.7 Hz, 1H), 4.25 (dd, J=2.6, 4.7 Hz, 2H), 2.58-2.41 (m, 1H), 2.10-1.92 (m, 1H). Anal Calcd for C₁₈ H₁₆ O₅ +1H₂ O: C, 67.49; H, 5.66. Found: C, 67.34; H, 5.42.

Example 23 3,4-Dihydroxy-5-[2-(quinoline-2-oxy)ethyl]-2(5H)-furanone

Mitsunoble coupling of 0.17 g (1.2 mmol) of 2-hydroxyquinoline with 0.34 g (1.0 mmol) of 3,4-dibenzyloxy-5-(2-hydroxyethyl)-2(5H)-furanone and subsequent benzyl group deprotection by hydrogenation were performed in a similar manner as described in the synthesis of 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone to provide 50 mg (17% yield) of 3,4-dihydroxy-5-[2-(quinoline-2-oxy)ethyl]-2(5H)-furanone as a fluffy white solid after recrystallization from ether and hexanes: ¹ H NMR (acetone-d₆) δ 8.25-8.17 (m, 1H); 7.88-7.38 (m, 4H), 7.01-6.93 (m, 1H); 4.97 (dd, J=4.9, 8.7 H, 1H), 4.81-4.55 (m, 2H); 2.62-2.45 (m, 1H), 2.20-1.95 (m, 1H). Anal Calcd for C₁₅ H₁₃ NO₅ +0.5H₂ O: C, 60.81; H, 5.10; N, 4.72. Found: C, 61.04; H 5.04: N, 4.32.

Example 24 3,4-Dihydroxy-5-[2-(4,5-diphenyl-1,3-oxazole-2-thio)ethyl]-2(5H)-furanone

A suspension of 3.14 g (12.4 mmol) 4,5-diphenyl-2-thio-1,3-oxazole in 12 mL of THF under argon with stirring at -78° C. was treated with 4.9 mL (12.2 mmol) of 2.5M nBuLi. The reaction mixture was warmed to -5° C. and 1.1 g (4 mmol) of 3,4-dihydroxy-5-(2-iodoethyl)-2(5H)-furanone dissolved in 12 mL of HMPA was added at a rate to maintain the reaction temperature below 0° C. Stirring continued at 0 to -5° C. for 60 minutes followed by the addition of 100 mL of saturated NH₄ Cl solution. The mixture was extracted with 2×100 mL portions of ether/EtOAc (1/1). The organic fractions were combined and extracted with 3×50 mL of saturated NaHCO₃ solution. The bicarbonate extracts were combined, washed with 2×50 mL of ether, acidified to pH 1 with 10% HCl solution and extracted into 2×100 mL portions of ether. The ether extracts were combined and washed successively with 40 mL of H₂ O, 40 mL of brine, dried (MgSO₄) and concentrated to an oil.

Purification over SiO₂ using acetone/hexanes (1:1 to 2:3 to 7:3) provided a brown colored solid upon evaporation of solvent. The solid was taken up in 100 mL of ether and extracted with 3×50 mL of NaHCO₃ solution. The combined aqueous extracts were acidified with 10% HCl solution and extracted with 2×100 mL portions of ether. The organic portions were washed with 40 mL of H₂ O, 40 mL of brine, dried (MgSO₄) and concentrated to provide 875 mg (55% yield) of 3,4-dihydroxy-5-[2-(4,5-diphenyl-1,3-oxazole-2-thio)ethyl]-2(5H)-furanone as a white foam: mp 88-91° C., ¹ H NMR (acetone-d₆) δ 7.67-7.39 (m, 10H), 4.95 (dd, J=3.7, 8.7 Hz, 1H), 3.61-3.28 (m, 2H), 2.72-2.19 (m, 2H). ¹³ C NMR (acetone-d₆) δ 169.17, 159.13, 152.70, 147.65, 136.83, 132.60, 129.14 (2 C), 128.85 (2 C), 128.61, 128.11, 126.92, 118.91, 74.25, 32.69, 27.32. Anal Calcd for C₂₁ H₁₇ NO₅ S+0.25 H₂ O: C, 63.07; H, 4.41; N, 3.50. Found: C, 63.23; H, 4.70; N, 3.24.

Example 25 3,4-Dihydroxy-5-[2-(naphthyl-1-thio)ethyl]-2(5H)-furanone

1-Naphthalenethiol (430 μL, 3.1 mmol) and 0.27 g (1 mmol) of 3,4-dihydroxy-5-(2-iodoethyl)-2(5H)-furanone were reacted in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-[2-(4,5-diphenyl-1,3-oxazole-2-thio)ethyl]-2(5H)-furanone to provide 90 mg (30% yield) of 3,4-dihydroxy-5-[2-(naphthyl-1-thio)ethyl]-2(5H)-furanone as a colorless oil. Additional purification by chromatography over SiO₂ was not necessary for this compound: ¹ H NMR (acetone-d₆) δ 8.44-8.32 (m, 1H), 7.98-7.43 (m, 6H), 4.92 (dd, J=3.7, 8.7 Hz, 1H), 3.28-3.06 (m, 2H), 2.39-2.19 (m, 1H), 2.02-1.84 (m, 1H). Anal Calcd for C₁₆ H₁₄ O₄ S+0.25 H₂ O: C, 62.63; H, 4.76. Found C, 63.06; H, 5.19.

Example 26 3,4-Dihydroxy-5-[2-(naphthyl-2-thio)ethyl]-2(5H)-furanone

2-Naphthalenethiol (430 μL, 3.1 mmol) and 0.27 g (1 mmol) of 3,4-dihydroxy-5-(2-iodoethyl)-2(5H)-furanone were reacted in an analogous manner as described for the synthesis of 3,4-dihydroxy-5-[2-(4,5-diphenyl-1,3-oxazole-2-thio)ethyl]-2(5H)-furanone to provide 140 mg (46% yield) of 3,4-dihydroxy-5-[2-(naphthyl-2-thio)ethyl]-2(5H)-furanone as a white powder after trituration with ether and hexanes. Additional purification by chromatography over SiO₂ was not necessary for this compound: ¹ H NMR (acetone-d₆) δ 7.95-7.82 (m, 4H), 7.58-7.40 (m, 3H), 4.92 (dd, J=3.7, 8.7 Hz, 1H), 3.34-3.08 (m, 2H), 2.42-2.21 (m, 1H), 2.02-1.86 (m, 1H). ¹³ C NMR (acetone-d₆) δ 169.53, 153.03, 134.48, 134.09, 132.29, 128.99, 128.13, 127.49, 127.41, 127.08, 126.65, 126.14, 118.68, 74.25, 32.33, 27.81. Anal Calcd for C₁₆ H₁₄ O₄ S: C, 63.56; H, 4.67. Found: C, 63.44; H, 4.58.

Example 27 3,4-Dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone

To a flame dried reaction flask fitted with an argon inlet, septum and magnetic stir bar, were added 58 mg (0.05 mmol) of Pd(PPh₃)₄, 225 μL (2.0 mmol) of iodobenzene, 0.17 g (1.0 mmol) of 5-(3-butynyl)-3,4-dihydroxy-2(5H)-furanone, 2 mL of pyrrolidine and 20 mg (0.10 mmol) of copper (I) iodide. The flask was protected from light (foil) and the yellow mixture was stirred at room temperature until the starting 5-(3-butynyl)-3,4-dihydroxy-2(5H)-furanone was not visible by TLC analysis (CHCl₃ :MeOH 9:1). The reaction mixture was poured into a mixture of 50 g of ice and 10 mL of 37% HCl, and extracted with 2×50 mL of ether. The ether extracts were combined and washed with 2×20 mL of 10% aqueous HCl solution, 20 mL of H₂ O, 20 mL of brine, dried (MgSO₄) and concentrated.

The residue was dissolved in 30 mL of ether and extracted with 3×15 mL of saturated NaHCO₃ solution. The bicarbonate extracts were pooled and washed with 10 mL of ether, acidified to pH 2 with 10% HCl solution and extracted with 2×25 mL of ether. The ether extracts were combined and washed with 10 mL of H₂ O, 3 mL of 10% (w/w) NaHCO₃ solution, 10 mL of H₂ O, 10 mL of brine, dried (MgSO₄) and concentrated to provide 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone as a white solid: mp 145-146° C.; ¹ H NMR (acetone-d₆) δ 7.35-7.15 (m, 5H), 4.75 (dd, J=3.4, 8.2 Hz, 1H), 2.50-2.40 (m, 2H), 2.20-2.05 (m, 1H), 1.75-1.60 (m, 1H); ¹³ C NMR (acetone-d₆) δ 170.2, 153.8, 132.3, 129.2, 128.7, 124.6, 119.0, 89.3, 82.1, 74.9, 32.4, 15.3.

Example 28 3,4-Dihydroxy-5-[(4-(2-methyl)phenyl)-3-butynyl]-2(5H)-furanone

5-(3-Butynyl)-3,4-dihydroxy-2(5H)-furanone (0.17 g, 1.0 mmol) and 256 μL (2.0 mmol) of 2-iodotoluene were coupled in an analogous fashion as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone. The residue was purified over silica gel using CHCl₃ /MeOH (96/4) as eluant to provide 3,4-dihydroxy-5-[(4-(2-methyl)phenyl)-3-butynyl]-2(5H)-furanone as a light yellow solid: mp 111-112° C., ¹ H NMR (CDCl₃) δ 7.37-7.07 (m, 4H), 5.01 (dd, J=3.5, 8.5 Hz, 1H), 2.69-2.65 (m, 2H), 2.40 (s, 3H), 2.39-2.27 (m, 1H), 1.97-1.86 (m, 1H); ¹³ C NMR (CDCl₃) δ 173.6, 155.8, 140.0, 131.9, 129.3, 127.9, 125.5, 123.1, 117.5, 91.5, 80.9, 76.4, 31.3, 20.7, 15.3; Anal Calcd for C₁₅ H₁₄ O₄ : C, 69.76; H, 5.46. Found: C, 69.41; H, 5.58.

Example 29 3,4-Dihydroxy-5-[(4-(2-(2Z-hexenyl))phenyl)-3-butynyl]-2(5H)-furanone

5-(3-Butynyl)-3,4-dihydroxy-2(5H)-furanone (0.34 g, 2.0 mmol) and 1.1 g (4.0 mmol) of 2-(2Z-hexenyl)iodobenzene were coupled in an analogous fashion as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone. The residue was purified over silica gel using CHCl₃ /MeOH (96/4) as eluant and dried at 0.05 mm Hg at 58° C. for 2 h to provide 100 mg (17% yield) of 3,4-dihydroxy-5-[(4-(2-(2Z-hexenyl))phenyl)-3-butynyl]-2(5H)-furanone as a yellow oil: ¹ H NMR (acetone-d₆) δ 7.43-7.15 (m, 4H), 5.70-5.45 (m, 2H), 4.91 (dd, 1H, J=3.4, 8.3 Hz), 3.57 (d, 2H, J=5.9 Hz), 2.66 (t, 2H, J=7.0 Hz), 2.37-2.11 (m, 3H), 2.00-1.85 (m, 1H), 1.48-1.29 (m, 2H), 0.93 (t, 3H, J=7.3 Hz); Anal Calcd for C₂₀ H₂₂ O₄ +0.2 H₂ O: C, 72.80; H, 6.84 Found: C, 72.99; H, 6.96.

Example 30 3,4-Dihydroxy-5-[(4-(2-(phenylthio)methyl)phenyl)-3-butynyl]-2(5H)-furanone

5-(3-Butynyl)-3,4-dihydroxy-2(5H)-furanone (0.12 g, 0.71 mmol) and 0.35 g (1.1 mmol) of 2-(phenylthio)methyl-1-iodobenzene were coupled in an analogous fashion as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone. The residue was purified over silica gel using CHCl₃ /MeOH/AcOH (96/3/1) as eluant and dried at 0.05 mm Hg at 58° C. for 2 h to provide 180 mg (69%) of 3,4-dihydroxy-5-[(4-(2-(phenylthio)methyl)phenyl)-3-butynyl]-2(5H)-furanone a light yellow oil: ¹ H NMR (acetone-d₆) δ 7.44-7.19 (m, 9H), 4.90 (dd, J=3.3, 8.3 Hz, 1H), 4.36 (s, 2H), 2.63 (t, J=7.6 Hz, 2H), 2.28-2.21 (m, 1H), 1.90-1.81 (m, 1H); Calcd for C₂₁ H₁₈ O₄ S: C, 68.85; H, 4.95. Found: C, 68.63; H, 5.11.

Example 31 3,4-Dihydroxy-5-[(4-(2-phenylsulfonamide-(N-butyl))-3-butynyl]-2(5H)-furanone

5-(3-Butynyl)-3,4-dihydroxy-2(5H)-furanone (0.17 g, 1.0 mmol) and 400 mg (1.2 mmol) of N-butyl-2-iodobenzenesulfonamide were coupled in an analogous fashion as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone. The residue was purified over silica gel using CHCl₃ /MeOH/AcOH (500/16/0.5) as eluant and dried at 0.05 mm Hg at 58° C. for 2 h to provide 3,4-dihydroxy-5-[(4-(2-phenylsulfonamide-(N-butyl))-3-butynyl]-2(5H)-furanone as a light yellow oil: ¹ H NMR (acetone-d₆) δ 8.00-7.96 (m, 1H), 7.59-7.55 (m, 1H), 7.33-7.24(m, 2H), 6.66(s, 1H), 4.82 (dd, J=3.4, 8.3 Hz, 1H), 3.44-3.36 (m, 2H), 3.23-3.14 (m, 2H), 2.52-2.45 (m, 1H), 2.00-1.94 (m, 1H), 1.69-1.53 (m, 2H), 1.43-1.29 (m, 2H), 0.81 (t, J=7.2 Hz, 3H); ¹³ C NMR (acetone-d₆) δ 169.8, 153.5, 141.6, 137.6, 130.0, 124.2, 123.8, 120.9, 118.6, 114.4, 108.7, 74.8, 53.6, 32.0, 24.9, 24.1, 20.9, 12.9; Anal Calcd for C₁₈ H₂₁ NO₆ S: C, 56.99; H, 5.58; N, 3.69. Found: C, 56.71; H, 5.65; N, 3.48.

Example 32 3,4-Dihydroxy-5-[4-(2-naphthyl)-3-butynyl]-2(5H)-furanone

5-(3-Butynyl)-3,4-dihydroxy-2(5H)-furanone (0.17 g, 1.0 mmol) and 300 μL (2.0 mmol) of 2-iodonaphthalene were coupled in an analogous fashion as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone. The residue was purified over silica gel using CHCl₃ /MeOH/AcOH (96/3/1) as eluant and dried at 0.05 mm Hg at 58° C. for 2 h to provide 230 mg (75%) of 3,4-dihydroxy-5-[4-(2-naphthyl)-3-butynyl]-2(5H)-furanone as a yellow wax: ¹ H NMR (acetone-d₆) δ 8.4-8.3 (m, 1H), 7.96-7.88 (m, 2H), 7.70-7.43 (m, 4H), 4.98 (dd, J=3.4, 8.3 Hz, 1H), 2.82-2.75 (m, 2H), 2.48-2.29 (m, 1H), 2.00-1.85 (m, 1H); Anal Calcd for C₁₈ H₄ 0.5 H₂ O: C, 71.27; H, 4.98. Found: C, 71.33; H, 4.87.

Example 33 3,4-Dihydroxy-5-[(4-(2-(propylthio)methyl)phenyl)-3-butynyl]-2(5H)-furanone

5-(3-Butynyl)-3,4-dihydroxy-2(5H)-furanone (0.17 g, 1.0 mmol) and 440 mg (1.5 mmol) of 2-(propylthio)methyl]-iodobenzene were coupled in an analogous fashion as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone. The residue was purified over silica gel using CHCl₃ /MeOH/AcOH (500/16/0.5) as eluant and dried at 0.05 mm Hg at 58° C. for 2 h to provide 240 mg (72% yield) of 3,4-dihydroxy-5-[(4-(2-(propylthio)methyl)phenyl)-3-butynyl]-2(5H)-furanone as a yellow oil: ¹ H NMR (acetone-d₆) δ 7.44-7.21 (m, 4H), 4.90 (dd, J=3.4, 8.3 Hz, 1H), 3.89 (s, 2H), 2.70-2.63 (m, 2H), 2.48-2.41 (m, 2H), 2.26-2.21 (m, 1H), 1.90-1.81 (m, 1H), 1.64-1.53 (m, 2H), 0.93 (t J=7.3 Hz, 3H); Anal Calcd for C₁₈ H₂₀ O₄ S: C, 65.05; H, 6.07. Found: C, 64.51; H, 6.28.

Example 34 3,4-Dihydroxy-5-[(4-(2-(1-pentylthio)methyl)phenyl)-3-butynyl]-2(5H)-furanone

5-(3-Butynyl)-3,4-dihydroxy-2(5H)-furanone (84 mg, 0.5 mmol) and 240 mg (0.75 mmol) of 2-(methyl-1-pentylsulfide)iodobenzene were coupled in an analogous fashion as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone. The residue was purified over silica gel using CHCl₃ /MeOH/AcOH (500/16/0.5) as eluant and dried at 0.05 mm Hg at 58° C. for 2 hours to provide 3,4-dihydroxy-5-[(4-(2-(pentylthio)methyl)phenyl)-3-butynyl]-2(5H)-furanone: ¹ H NMR (acetone-d₆) δ 7.43-7.21 (m, 4H), 4.95 (dd, J=3.4, 8.4 Hz, 1H), 3.89 (s, 2H), 2.70-2.63 (m, 2H), 2.50-2.43 (m, 2H), 2.26-2.21 (m, 1H), 2.00-1.81 (m, 1H), 1.66-1.45 (m, 2H), 1.43-1.20 (m, 4H), 0.87 (t, J=7.2 Hz, 3H); Anal Calcd for C₂₀ H₂₄ O₄ S+0.5 H₂ O: C 65.02; H, 6.82. Found: C, 65.38; H, 6.69.

Example 35 3,4-Dihydroxy-5-[(4-(2-(propylsulfonyl)methyl)phenyl)-3-butynyl]-2(5H)-furanone

5-(3-Butynyl)-3,4-dihydroxy-2(5H)-furanone (236 mg, 1.2 mmol) and 600 mg (1.5 mmol) of 2-methyl-(1-propylsulfone)iodobenzene were coupled in an analogous fashion as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone. The residue was purified over silica gel using CHCl₃ /MeOH/AcOH (500/16/0.5) as eluant and dried at 0.05 mm Hg at 58° C. for 2 h to provide 250 mg (50% yield) of 3,4-dihydroxy-5-[(4-(2-(propylsulfonyl)methyl)phenyl)-3-butynyl]-2(5H)-furanone as a light yellow oil: ¹ H NMR (acetone-d₆) δ 7.56-7.34 (m, 4H), 4.96 (dd, J=3.4, 8.2 Hz, 1H), 4.57 (s, 2H), 3.03-2.95 (m, 2H), 2.71-2.64 (m, 2H), 2.35-2.26 (m, 1H), 1.94-1.70 (m, 3H), 1.02 (t, J=7.4 Hz, 3H); ¹³ C NMR (acetone-d₆) δ 169.9, 153.5, 132.9, 132.1, 131.0, 128.9, 128.5, 125.3, 118.6, 94.0, 79.6, 74.4, 57.2, 54.0, 31.5, 15.7, 14.8, 12.7; Anal Calcd for C₁₈ H₂₀ O₆ S: C, 59.34; H, 5.53. Found: C, 58.93; H, 5.76.

Example 36 3,4-Dihydroxy-5-[2-(4-(4-fluorophenylmethyl)thiophene)-(3-butynyl)]-2(5H)-furanone

5-(3-Butynyl)-3,4-dihydroxy-2(5H)-furanone (750 mg, 4.5 mmol) and 2.6 g (8.2 mmol) of 4-(4-fluorophenylmethyl)-2-iodothiophene were coupled in an analogous fashion as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone. The residue was purified over silica gel using CHCl₃ /MeOH/AcOH 500/15/0.5) as eluant and dried at 0.05 mm Hg at 58° C. for 2 h to provide 1.2 g (75% yield) of 3,4-dihydroxy-5-[2-(4-(4-fluorophenylmethyl)thiophene)-(3-butynyl)]-2(5H)-furanone as a brown wax: mp 119-121° C. 1H NMR (acetone-d₆) δ 7.38-7.25 (m, 2H), 7.13-6.99 (m, 3H), 6.78-6.74 (m, 1H), 4.84 (dd, J=3.3, 8.1 Hz, 1H), 4.14 (s, 2H), 2.59 (t, J=7.1 Hz, 2H), 2.38-2.14 (m, 1H), 1.90-1.69 (m, 1H); ¹³ C NMR (acetone-d₆) δ 169.19, 164.04, 157.29, 152.78, 145.79, 136.74, 131.80, 130.80, 130.47, 125.54, 122.74, 118.84, 115.89, 115.03, 92.44, 74.90, 74.31, 35.14, 31.84, 15.02; Anal Calcd for C₁₉ H₁₅ FO₄ S: C, 63.69; H, 4.22. Found: C, 63.42; H, 4.33.

Example 37 3,4-Dihydroxy-5-(4-phenylbutanyl)-2(5H)-furanone

Quinoline (70 μL, 0.6 mmol), 15 mg of 5% Pd/BaSO₄ and 61 mg (0.25 mmol) of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone were combined in 20 mL of ethanol and hydrogenated at atmospheric pressure until 12 mL (0.5 mmol) of H₂ was consumed as measured by a H₂ O filled burette. The catalyst was removed by filtration through two #1 fluted filter papers and the solution was concentrated to a volume of about 5 mL, taken up in SOmL of ether and washed with 3×15 mL of 5% aqueous HCl, 20 mL of H₂ O and 20 mL of brine, dried (MgSO₄) and concentrated to provide 3,4-dihydroxy-5-(4-phenylbutanyl)-2(5H)-furanone as a brown wax: ¹ H NMR (acetone-d₆) δ 7.28-7.13 (m, 5H), 4.66 (dd, J=3.4, 7.2 Hz, 1H), 2.62 (t, J=7.7, 2H), 2.00-1.93 (m, 1H), 1.69-1.42 (m, 5H); ¹³ C NMR (acetone-d₆) δ 170.7, 154.9, 143.3, 129.2, 129.1, 126.5, 118.6, 76.2, 36.3, 32.7, 32.1, 24.6. Anal Calcd for C₁₄ H₁₆ O₄ +0.25 H₂ O: C, 66.52; H, 6.58. Found: C, 66.71; H, 6.75.

Example 38 3,4-Dihydroxy-5-[(4-phenyl)-3Z-butenyl]-2(5H)-furanone

Quinoline (70 μL, 0.6 mmol), 15 mg of 5% Pd/BaSO₄ and 62 mg (0.25 mmol) of 3,4-dihydroxy-5-[(4-phenyl)-3-butynyl]-2(5H)-furanone were combined in 20 mL of ethanol and hydrogenated at atmospheric pressure until 6 mL (0.25 mmol) of H₂ was consumed as measured by a H₂ O filled burette. The catalyst was removed by filtration through 2 fluted filter papers and the solution was concentrated, taken up in 50 mL of ether and washed with 3×5 mL of 5% aqueous HCl, 20 mL of H₂ O and 20 mL of brine, dried (MgSO₄) and concentrated to give 3,4-dihydroxy-5-[(4-phenyl)-3Z-butenyl]-2(5H)-furanone as the major constituent in a mixture of alkyne, cis alkene and alkane (1.0/5.0/0.5) as determined by ¹ H NMR spectra: ¹ H NMR (CDCl₃) δ 7.34-7.14 (m, 5H), 6.46 (d, J=11.5 Hz, 1H), 5.65-5.57 (m, 1H), 4.77 (dd, 3.5, 8.0 Hz, 1H), 2.49 (dd, J_(ab) =7.6 Hz, 2H), 2.16-2.09 (m, 1H), 1.80-1.70 (m, 1H); ¹³ C NMR (CDCl₃) δ 173.4, 155.9, 137.1, 130.4, 130.3, 128.7, 128.3, 128.3, 126.8, 117.5, 77.2, 31.8, 23.5.

Example 39 3,4-Dihydroxy-5[(4-(2-methyl)phenyl)-3Z-butenyl]-2(5H)-furanone

3,4-Dihydroxy-5[(4-(2-methyl)phenyl)-3-butenyl]-2(5H)-furanone (65 mg, 0.25 mmol) was reduced in a similar manner as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3Z-butenyl]-2(5H)-furanone to produce 3,4-dihydroxy-5[(4-(2-methyl)phenyl)-3Z-butenyl]-2(5H)-furanone as an oil consisting of only the cis isomer as observed by the ¹ H NMR spectra. ¹ H NMR (CDCl₃) δ 7.34-7.20 (m, 4H), 6.59 (d, J=11.4 Hz, 1H), 5.81-5.73 (m, 1H), 4.81 (dd, J=3.4, 8.2 Hz, 1H), 2.49-2.35 (m, 2H), 2.33 (s, 3H), 2.17-2.13 (m, 1H), 1.81-1.75 (m, 1H); ¹³ C NMR (CDCl₃) δ 173.6, 156.0, 136.2, 136.2, 130.2, 129.9, 129.6, 128.8, 127.1, 125.5, 117.4, 77.3, 31.9, 23.4, 19.9.

Example 40 3,4-Dihydroxy-5[(4-(2-(2Z-hexenyl))phenyl)-3Z-butenyl]-2(5H)-furanone

3,4-Dihydroxy-5[(4-(2-(2-hexynyl))phenyl)-3Z-butenyl]-2(5H)-furanone (75 mg, 0.25 mmol) was reduced in a similar manner as described for the synthesis of 3,4-dihydroxy-5-[(4-phenyl)-3Z-butenyl]-2(5H)-furanone to produce 3,4-dihydroxy-5[(4-(2-(2Z-hexenyl))phenyl)-3Z-butenyl]-2(5H)-furanone as an oil consisting of only the cis isomer as observed by the ¹ H NMR spectra and contaminated with less than 5% of starting material, which was not separable from the product: ¹ H NMR (acetone-d₆) δ 7.25-7.15 (m, 4H), 6.59 (d, 1H, J=11.4 Hz), 5.81-5.76 (m, 1H), 5.51-5.43 (m, 2H), 4.71 (dd, 1H, J=3.5, 7.6 Hz), 3.44-3.25 (m, 2H), 2.40-1.90 (m, 5H), 1.76-1.58 (m, 1H), 1.50-1.32 (m, 2H), 0.94 (t, 3H, J=7.3 Hz). Anal Calcd for C₂₀ H₂₄ O₄ +0.25 H₂ O: C, 71.20; H. 7.47. Found: C, 70.97; H, 7.32.

The following is a list of references related to the above disclosure. These references should be considered as incorporated by reference in their entirety.

1. Shimuzu. T., et al. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthetase from arachidonic acid. Pro. Natl. Acad, Sci. 81:689-693, (1984).

2. Egan, R W and Gale P H, Inhibition of mammalian 5-lipoxygenase by aromatic disulfides, J. Biol. Chem. 260: 11554-11559, (1985).

3. Evans, AT, et al Actions of cannabis constituents on enzymes of arachidonic metabolism: anti-inflammatory potential. Biochem Pharm. 36:2035-2037, (1987).

4. Boopathy, R and Baiasubrarnanian A S. Purification and characterization of sheep platelet cyclooxygenase. Biochem J. 239:371-377, (1968).

5. O'Sullivan, M G et al, Lipopolysaccharide induces prostaglandin H synthase-2 in alveolar macrophages. Biochem. Biophys. Res. Comm. 187: 1123-1127, (1992).

6. Mansuy D. et al, A new potent inhibitor of lipid peroxidation in vitro and in vivo, the hepatoprotective drug anisyldithiolthione. Biochem. Biophys. Res. Comm. 135:1015-1021, (1986). 

What is claimed is:
 1. A racemic or optically active compound of the formula I: ##STR21## wherein R is hydrogen, phenyl, or a lower alkyl; L is a linker moiety selected from the group consisting of oxygen, sulfur, nitrogen, acetylene, a cis or trans carbon--carbon double bond, an ester, carbonate, urea, amide and carbamate; m is 1, n is 0 to 4, Aryl is a substituted or unsubstituted aryl group; with the proviso that when R is hydrogen, L is sulfur, n=2 and Aryl is phenyl, said phenyl is substituted other than with a hydroxy, alkyl, alkoxy, alkenyl or alkenyloxy group; or a pharmaceutically acceptable salt thereof.
 2. A compound according to claim 1 of the formula Ib ##STR22## wherein n is 0 to 4 and Aryl is a mono-substituted or unsubstituted aryl group; or a pharmaceutically acceptable salt thereof.
 3. A compound according to claim 2 which is 3,4-dihydroxy-5-[(4-(2-(2Z-hexenyl))phenyl)-3-butynyl]-2(5H)-furanone.
 4. A compound according to claim 2 which is 3,4-dihydroxy-5-[(4-(2-(phenylthio)methyl)phenyl)-3-butynyl]-2(5H)-furanone.
 5. A compound according to claim 2 which is 3,4-dihydroxy-5-[4-(2-naphthyl)-3-butynyl]-2(5H)-furanone.
 6. A compound according to claim 2 which is 3,4-dihydroxy-5-[2-(4-(4-fluorophenylmethyl)thiophene)-(3-butynyl)]-2(5H)-furanone.
 7. A compound according to claim 1 of the formula Ic ##STR23## wherein n is 0 to 4 Aryl is a substituted or unsubstituted aryl group; or a pharmaceutically acceptable salt thereof.
 8. A compound according to claim 7 which is 3,4-dihydroxy-5-[2-(4,5-diphenyl-1,3-oxazole-2-thio)ethyl]-2(5H)-furanone.
 9. A compound according to claim 7 which is 3,4-dihydroxy-5-[2-(naphthyl-1-thio)ethyl]-2(5H)-furanone.
 10. A compound according to claim 7 which is 3,4-dihydroxy-5-[2-(naphthyl-2-thio)ethyl]-2(5H)-furanone.
 11. A compound according to claim 1 of the general formula Id ##STR24## wherein n is 0 to 4 and Aryl is a mono-substituted or unsubstituted aryl group; or a pharmaceutically acceptable salt thereof.
 12. A compound according to claim 11 which is 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone.
 13. A compound according to claim 11 which is 3,4-dihydroxy-5-[2-(flavone-6-oxy)ethyl]-2(5H)-furanone.
 14. A compound according to claim 11 which is 5-[2-(dibenzofuran-2-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone.
 15. A compound according to claim 11 which is 3,4-dihydroxy-5-[2-(1-naphthoxy)ethyl]-2(5H)-furanone.
 16. A compound according to claim 11 which is 3,4-dihydroxy-5-[2-(diphenylmethane-2-oxy)ethyl]-2(5H)-furanone.
 17. A compound according to claim 11 which is 5-[2-((1,1'-biphenyl)-4-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone.
 18. A pharmaceutical composition comprising an effective amount of a racemic or optically active compound of the general formula I: ##STR25## wherein R is hydrogen, phenyl, or a lower alkyl; L is a linker moiety selected from the group consisting of oxygen, sulfur, nitrogen, acetylene, a cis or trans carbon--carbon double bond, an ester, carbonate, urea, amide and carbamate; m is 1, n is 0 to 4, Aryl is a substituted or unsubstituted aryl group; with the proviso that when R is hydrogen, L is sulfur, n=2 and Aryl is phenyl, said phenyl is substituted other than with a hydroxy, alkyl, alkoxy, alkenyl or alkenyloxy group; or a pharmaceutically acceptable salt thereof; together with a pharmaceutically acceptable carrier therefor.
 19. A composition according to claim 18 wherein the compound is of the formula Ib ##STR26## wherein n is 0 to 4, and Aryl is a substituted or unsubstituted aryl group; or a pharmaceutically acceptable salt thereof.
 20. A composition according to claim 19 wherein the compound is 3,4-dihydroxy-5-[(4-(2-(2Z-hexenyl))phenyl)-3-butynyl]-2(5H)-furanone.
 21. A composition according to claim 19 wherein the compound is 3,4-dihydroxy-5-[(4-(2-(phenylthio)methyl)phenyl)-3-butynyl]-2(5H)-furanone.
 22. A composition according to claim 19 wherein the compound is 3,4-dihydroxy-5-[4-(2-naphthyl)-3-butynyl]-2(5H)-furanone.
 23. A composition according to claim 19 wherein the compound is 3,4-dihydroxy-5-[2-(4-(4-fluorophenylmethyl)thiophene)-(3-butynyl)]-2(5H)-furanone.
 24. A composition according to claim 18 wherein the compound is of the formula Ic ##STR27## wherein n is 0 to 4, and Aryl is a substituted or unsubstituted aryl group; or a pharmaceutically acceptable salt thereof.
 25. A composition according to claim 24 wherein the compound is 3,4-dihydroxy-5-[2-(4,5-diphenyl-1,3-oxazole-2-thio)ethyl]-2(5H)-furanone.
 26. A composition according to claim 24 wherein the compound is 3,4-dihydroxy-5-[2-(naphthyl-1-thio)ethyl]-2(5H)-furanone.
 27. A composition according to claim 24 wherein the compound is 3,4-dihydroxy-5-[2-(naphthyl-2-thio)ethyl]-2(5H)-furanone.
 28. A composition according to claim 18 wherein the compound is of the general formula Id ##STR28## wherein n is 0 to 4, and Aryl is a substituted or unsubstituted aryl group; or a pharmaceutically acceptable salt thereof.
 29. A composition according to claim 28 wherein the compound is 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone.
 30. A composition according to claim 28 wherein the compound is 3,4-dihydroxy-5-[2-(flavone-6-oxy)ethyl]-2(5H)-furanone.
 31. A composition according to claim 28 wherein the compound is 5-[2-(dibenzofuran-2-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone.
 32. A composition according to claim 28 wherein the compound is 3,4-dihydroxy-5-[2-(1-naphthoxy)ethyl]-2(5H)-furanone.
 33. A composition according to claim 28 wherein the compound is 3,4-dihydroxy-5-[2-(diphenylmethane-2-oxy)ethyl]-2(5H)-furanone.
 34. A composition according to claim 28 wherein the compound is 5-[2-((1,1'-biphenyl)-4-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone.
 35. A method of treating a pathology involving acute or chronic inflammation which comprises administration to a patient in need of such therapy an effective amount of a racemic or optically active compound of the formula ##STR29## wherein R is hydrogen, phenyl, or a lower alkyl; L is a linker moiety selected from the group consisting of oxygen, sulfur, nitrogen, acetylene, a cis or trans carbon--carbon double bond, an ester, carbonate, urea, amide and carbamate; m is 1, n is 0 to 4, Aryl is a substituted or unsubstituted aryl group; with the proviso that when R is hydrogen, L is sulfur, n=2 and Aryl is phenyl, said phenyl is substituted other than with a hydroxy, alkyl, alkoxy, alkenyl or alkenyloxy group; or a pharmaceutically acceptable salt thereof.
 36. A method according to claim 35 wherein the compound is of the formula Ib ##STR30## wherein n is 0 to 4, and Aryl is a substituted or unsubstituted aryl group; or a pharmaceutically acceptable salt thereof.
 37. A method according to claim 36 wherein the compound is 3,4-dihydroxy-5-[(4-(2-(2Z-hexenyl))phenyl)-3-butynyl]-2(5H)-furanone.
 38. A method according to claim 36 wherein the compound is 3,4-dihydroxy-5-[(4-(2-(phenylthio)methyl)phenyl)-3-butynyl]-2(5H)-furanone.
 39. A method according to claim 36 wherein the compound is 3,4-dihydroxy-5-[4-(2-naphthyl)-3-butynyl]-2(5H)-furanone.
 40. A method according to claim 36 wherein the compound is 3,4-dihydroxy-5-[2-(4-(4-fluorophenylmethyl)thiophene)-(3-butynyl)]-2(5H)-furanone.
 41. A method according to claim 35 wherein the compound is of the formula Ic ##STR31## wherein n is 0 to 4, and Aryl is a substituted or unsubstituted aryl group; or a pharmaceutically acceptable salt thereof.
 42. A method according to claim 41 wherein the compound is 3,4-dihydroxy-5-[2-(4,5-diphenyl-1,3-oxazole-2-thio)ethyl]-2(5H)-furanone.
 43. A method according to claim 41 wherein the compound is 3,4-dihydroxy-5-[2-(naphthyl-1-thio)ethyl]-2(5H)-furanone.
 44. A method according to claim 41 wherein the compound is 3,4-dihydroxy-5-[2-(naphthyl-2-thio)ethyl]-2(5H)-furanone.
 45. A method according to claim 35 wherein the compound is of the formula Id ##STR32## wherein n is 0 to 4, and Aryl is a substituted or unsubstituted aryl group; or a pharmaceutically acceptable salt thereof.
 46. A method according to claim 45 wherein the compound is 3,4-dihydroxy-5-[2-(4-phenoxy)phenoxyethyl]-2(5H)-furanone.
 47. A method according to claim 45 wherein the compound is 3,4-dihydroxy-5-[2-(flavone-6-oxy)ethyl]-2(5H)-furanone.
 48. A method according to claim 45 wherein the compound is 5-[2-(dibenzofuran-2-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone.
 49. A method according to claim 45 wherein the compound is 3,4-dihydroxy-5-[2-(1-naphthoxy)ethyl]-2(5H)-furanone.
 50. A method according to claim 45 wherein the compound is 3,4-dihydroxy-5-[2-(diphenylmethane-2-oxy)ethyl]-2(5H)-furanone.
 51. A compound according to claim 45 wherein the compound is 5-[2-((1,1'-biphenyl)-4-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone.
 52. A method of treating a pathology in which reactive oxygen species and inflammatory mediators are contributing deleterious factors which comprises administration to a patient in need of such therapy an effective amount of a racemic or optically active compound of the formula ##STR33## wherein R is hydrogen, phenyl, or a lower alkyl; L is a linker moiety selected from the group consisting of oxygen, nitrogen, acetylene, a cis or trans carbon--carbon double bond, an ester, carbonate, urea, amide and carbamate; m is 1, n is 0 to 4, Aryl is a substituted or unsubstituted aryl group; with the proviso that when R is hydrogen, L is sulfur, n=2 and Aryl is phenyl, said phenyl is substituted other than with a hydroxy, alkyl, alkoxy, alkenyl or alkenyloxy group; or a pharmaceutically acceptable salt thereof.
 53. The method of claim 52 wherein said pathology comprises acute or chronic inflammatory disorders.
 54. The method of claim 53 wherein said acute or chronic inflammatory disorder is asthma, rheumatoid arthritis, inflammatory bowel disease, or acute respiratory distress syndrome.
 55. The method of claim 52 wherein said pathology comprises neurodegenerative disorders.
 56. The method of claim 55 wherein said neurodegenerative disorder is Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, traumatic brain injury or multiple sclerosis.
 57. The method of claim 52 wherein said pathology comprises cardiovascular disease.
 58. The method of claim 57 wherein said cardiovascular disease is atherosclerosis.
 59. The method of claim 52 wherein said pathology comprises a viral disease.
 60. The method of claim 59 wherein said viral disease is AIDS.
 61. The method of claim 52 wherein said pathology comprises a skin disease. 